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ABSTRACT OF THE DISSERTATION

Exploring Fatty Acid Metabolism for the Biosynthesis of Non-Natural Chemicals
by
Wen Jiang
Doctor of Philosophy in Energy, Environmental and Chemical Engineering
Washington University in St. Louis, 2018
Professor Fuzhong Zhang, Chair

The global energy crisis and increasing environmental concerns have spurred the sustainable
production of biofuels and other fossil-fuel-derived chemicals. One approach is to engineer
microbial metabolic pathways to convert renewable feedstocks (e.g. lignocellulosic biomass) to
compounds that have structures similar to those of petroleum-derived fuels and chemicals. The
microbial fatty acid (FA) biosynthetic pathway is attractive because FAs are common precursors
that can be converted to several types of chemicals, including alkanes, alkenes, alcohols, and esters.
These chemicals have numerous applications as fuels, fragrances, emollients, plasticizers,
thickeners, and detergents. Most work has used Escherichia coli as the microbial host due to its
exceptionally high rate of fatty acid biosynthesis.
To broaden the use of FA-derived compounds, it is important to diversify the structure of
biosynthesized FAs. Unfortunately, wild-type E. coli synthesize only straight long-chain FAs
(mostly palmitic acid), which limits their range of application. On the other hand, chemicals
derived from non-natural fatty acids (NNFAs) have wider applications. For example, branchedchain FA-derived hydrocarbons have better combustion properties than their straight-chain
counterparts when used as fuels, and ω-hydroxy acids and di-acids are monomers for polymers.
xi

My dissertation work explored engineering E. coli metabolic pathways to produce NNFAs and
their derivatives. I started with the production branched-chain fatty acids (BCFAs), and showed
that high percentage BCFA (or derivatives) production can be achieved via my engineered strains.
The composition of BCFAs was controlled to produce even-chain-iso-, odd-chain-iso-, or oddchain-anteiso-BCFAs separately. Next, I partitioned the complete pathway into three modules: a
precursor formation module, an acyl-CoA activation and malonyl-ACP consumption module, and
a final product synthesis module. I engineered and tuned each module separately and combined
the optimal modules to produce a high percentage of branched-chain fatty alcohols, alkanes, and
esters. Finally, I established a new cell-free framework as a proof-of-concept for in vitro
production of fatty acid derivatives, providing a platform for rapid screening and prototyping of
fatty acid synthetic pathways to produce bifunctional fatty acid derivatives.
The findings of my work have provided a deeper understanding of the potential of the fatty
acid synthetic pathway for NNFA production, and the strain-engineering strategies used in this
dissertation will open new opportunities for efficient production of chemicals derived from
NNFAs.

xii

Chapter 1: Microbial production of nonnatural chemicals
1.1 Current progress in microbial bioproduction
The past decade has witnessed rapid advance in microbial bioproduction from renewable resources.
Various biosynthetic pathways have been constructed to produce chemicals with diverse structures,
and multiple metabolic engineering strategies have been developed to increase titers, yields,
productivities and system robustness. The feedstock choices have been expanded from food crops
(e.g., corns and oilseeds) to abundant and low-cost non-food biomass (e.g., corn stover and
switchgrass) [1], solid wastes (e.g., industrial wastes and sewage sludge) [2], natural resources
(syngas, methanol and methane) [3], and carbon dioxide [4]. Meanwhile, the fermentation host
choices have expanded beyond the traditional model microorganisms such as Escherichia coli and
Saccharomyces cerevisiae to a wide variety of non-model organisms. These new hosts variously
feature unique capabilities in assimilating target feedstock, adapting to specialized fermentation
conditions, and producing target chemicals in high efficiencies.

1.2 Strategies for pathway optimization
Once the metabolic pathway is established, several new strategies can be applied to optimize
the pathway and to increase product titers, yields, and productivities. Conventional concept of
metabolic engineering is to drive the metabolic flux into the production pathway. Various methods
have been developed to facilitate this step, including upregulating pathway enzymes [5], deleting
or downregulating competing pathways [6], and adjusting the global metabolism by engineering
1

transcriptional factors [7]. Meanwhile, an increasing number of strategies have been developed to
balance metabolic pathways and to engineer host cells by increasing their robustness, enhancing
cell viability, and regulating cell populations [8].
Metabolite overproduction often competes with natural metabolism for limited cellular
resources and disrupts the host’s homeostasis for some metabolites or cofactors [9], leading to
impaired cell growth [10]. Therefore, to increase the system robustness and thus to obtain high
efficient production, engineered metabolic pathway must be balanced by eliminating pathway
bottlenecks while preventing the accumulation of excess proteins or intermediates. A metabolic
pathway can be balanced statically via engineering promoters [11] or RBSs [12], or dynamically
via a metabolite biosensor to adjust flux in response to a rate-limiting or a toxic metabolite by
regulating its production and/or consumption [13, 14]. An alternative strategy to avoid adverse
effects on cell growth is to separate the production process from cell growth phase. Several
strategies were developed to induce the transition from growth phase to production, including
stationary phase signals [15], quorum sensing [16], and depletion of a nutrient [17] that is not
needed for metabolite production. For example, based on the Crabtree effect, a GAL regulatory
circuit was engineered in S. cerevisiae to autosense glucose depletion and simultaneously induce
the producing pathway [18, 19].
Furthermore, the accumulation of some products may trigger a variety of detrimental effects
on the host cells, mainly physiological changes of cell membranes. By altering the composition of
cell membranes FA (e.g. chain length, degree of saturation, and abundance of cyclic rings) [20]
and the distribution of phospholipid head groups [21], the engineered hosts could demonstrate
enhanced tolerance to various toxic compounds (such as alcohols, carboxylic acids and aromatic
compounds) and adverse industrial conditions (such as low pH and high temperature) [20].
2

In addition, the heterogeneity of producing cells strongly affects ensemble production [22, 23].
A recently developed strategy named PopQC positively links metabolite production with cell
growth, enabling the enrichment of high-producing variants from a heterologous culture and
leading to several folds enhancement in overall product titers [24]. Selecting non-genetic variants
is a promising new path to increase the production yield, with a strong potential for novel
development based on the system.

1.3 Metabolic pathways for the synthesis of non-natural
chemicals
Typically, based on the inherence of the biosynthetic pathway, the produced chemicals can be
broadly classified into three categories: 1) Natural chemicals, such as bioethanol and lactic acid,
which are produced inherently through a native pathway; 2) Non-natural chemicals, such as 1butanol and isobutanol, which are produced in a heterologous host strain by the establishment of
heterologous pathways and enzymes; 3) Non-natural created chemicals, which can only be
produced by creating synthetic enzymes and pathways with new functions. In this section, I intend
to give a brief but comprehensive overview of three heterologous pathways leading to non-natural
chemical production in E. coli.

1.3.1 α-keto acid pathway
Isobutanol pathway is a great example for non-natural chemical biosynthesis. By combining
the short-chain branched-chain amino acid biosynthetic pathway with the alcohol generation
pathway, short-chain alcohols (including isobutanol, 3-methyl-1-butanol, and 2-methyl-1-butanol)
were produced from cellular short-chain α-keto acid intermediates catalyzed by an α-keto acid
decarboxylase and an alcohol dehydrogenase [25](Figure 1-1, light blue). Furthermore, by altering
3

the substrate specificity of LeuABCD enzymes, the acyl chain length of α-keto acids was further
increased by recursively condensing with acetyl-CoA and releasing CO2. Using this strategy,
alcohols with medium chain-lengths (up to C8) or with branched/aromatic terminals were
produced [26] (Figure 1-1, green). Meanwhile, α-keto acids or their derived alcohols can also be
converted to short-chain acids [27] and alkanes [28], and to acetate-based esters [29].
Table 1- 1 The carbon efficiencies, cofactor balances, and highest titers produced from αketo acid pathway
Products
Carbon recovery from glucose
Cofactor imbalance
Highest titer
1-butanol
44.4%
+ 6 NADH
1 g/L [30]
isobutanol
66.7%
+ 1 NADH, - 1 NADPH
22 g/L [25]
3-methyl-1-butanol
55.6%
+ 4 NADH, - 1 NADPH
4.4 g/L [31]
2-methyl-1-butanol
83.3%
+ 1 NADH, - 3 NADPH 1.25 g/L [32]
1-pentanol
41.7%
+ 8 NADH
4.3 g/L [33]
1-hexanol
40.0%
+ 10 NADH
302 mg/L
[26]
1-heptanol
38.9%
+ 12 NADH
80 mg/L [26]
1-octanol
38.1%
+ 14 NADH
2.0 mg/L [26]

One advantage of the α-keto acid pathway is its ability to add one carbon atom at a time to the
acyl-chain, allowing precise control over chain-length. However, this chain elongation process
sacrifices carbon efficiency and accumulates NADH (Table 1-1), which might be the reason for
the lower titer of medium-chain alcohols (C6-C8) compared to that of isobutanol.

4

Figure 1- 1 Biofuels produced from the α-keto acid pathway (left) and non-decarboxylative
Claisen condensation pathway (right)
α-keto acids can be converted to aldehydes by an α-keto acid decarboxylase (Kivd). Aldehydes
can then be converted to alcohols by an aldehyde dehydrogenase (AdhE) or to alkanes by an
aldehyde decarbonylase (colored blue). α-keto acids can be elongated by a LeuABCD mutant to
yield longer chain α-keto acids (colored green). The natural-occurring non-decarboxylative
Claisen condensation pathway is colored purple. The engineered primers and extenders used in the
non-decarboxylative Claisen condensation pathway are colored grey.

1.3.2 Non-decarboxylative Claisen condensation pathway
Non-decarboxylative Claisen condensation pathway was first discovered in nature from
Clostridium kluyveri [34] (Figure 1-1, purple). In this pathway, two molecules of acetyl-CoA are
condensed to acetoacetyl-CoA, which is then reduced to butyrate by β-reduction reactions. In
contrast to the FA biosynthetic pathway that grows the carbon chain on ACP, the nondecarboxylative Claisen condensation pathway grows the carbon chain on CoA and uses acetylCoA or other short-chain acyl-CoAs as primers. Dellomonaco et al. engineered a synthetic nondecarboxylative Claisen condensation pathway to elongate carbon chains by reversing β-oxidation
pathway [35]. The elongation cycle can be terminated by an acyl-CoA reductase and an alcohol
5

dehydrogenase to produce straight-chain alcohols, or by an acyl-CoA thioesterase to produce
carboxylic acids. By switching thiolases and β-reduction enzymes, researchers further expanded
the primer from acetyl-CoA to six other ω-functionalized primers, and incorporated three different
extender units [36] (Figure 1, grey structures). This platform has greatly enlarged the structural
diversity of biosynthesized molecules, yielding a series of novel bioproducts, such as 2methylpentanoic acid and 2,3-dihydroxybutyric acid [36].
The non-decarboxylative Claisen condensation pathway has two distinctive advantages: the
ability to incorporate internal functional groups (including branch structures) into the product, and
the ability to orthogonally control the structures of both primers and extenders. This pathway will
become more versatile as new enzymes are discovered to incorporate more extenders and new
strategies are developed to precisely control the number and order of elongation cycles.

1.3.3 Isoprenoid pathway
The isoprenoid pathway utilizes C5 isopentenyl pyrophosphate (IPP) and dimethylallyl
pyrophosphate (DMAPP) as building blocks, which are produced from either the mevalonate
(MVA) or methylerythritol-4-phosphate (MEP) pathway (Figure 1-2). The carbon chain is
elongated by iterative assembly of IPP or DMAPP, generating polyisoprenoid diphosphates which
are then converted to terpenes or terpenoids by terpene synthases or polyisoprenoid diphosphate
modifying enzymes such as hydrolases or esterases.

6

Figure 1- 2 The isoprenoid pathway
Mevalonate pathway is colored light blue. MEP pathway is colored purple. AA-CoA: acetoacetylCoA; MVA: mevalonate; MVAP: mevalonate-5-phosphate; MVAPP: mevalonate-diphosphate;
MEP: 2-C-methylerythritol-4-phosphate; CDP-ME: 4-diphosphocytidyl-2-C-methylerythritol;
CDP-MEP: 4-diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate; HMB-PP: (E)-4-hydroxy3-methyl-but-2-enyl pyrophosphate.

Due to the diverse functionality of terpene synthases, the most outstanding feature of the
isoprenoid pathway is its capability to generate structurally diverse products. So far, thousands of
different terpene structures have been identified [37], and over hundreds of terpene synthases have
been sequenced [38]. However, most terpene synthases have not been characterized, and the links
between most terpene synthases to their corresponding terpene products have not been established.
New methods for high throughput characterization of new terpene synthases could facilitate the
discovery of new biosynthetic routes to various specialty chemicals.

7

1.4 Fatty acid pathway
The commercialization of biodiesel as the first-generation biofuels has attracted much
attention on fatty acid pathway. As oilseed-derived biodiesel suffers from inferior low-temperature
performance and competes with food supply, engineering efforts have been made to overproduce
microbial-based fatty acid-derived fuels and chemicals. Fatty acids (FAs) are biosynthesized in
vivo by either the discrete fatty acid synthase complex FASII (in most bacteria) or a multifunctional
FASI synthase (in eukaryotic cells). In E. coli, the initiation step is catalyzed by β-keto-acyl-ACP
synthetase III (FabH, encoded by fabH), which condenses acetyl-CoA with malonyl-ACP to form
acetoacetyl-ACP (Figure 1-3). The four-carbon acyl chain is then elongated on acyl carrier proteins
(ACPs) through repeated cycles of reactions catalyzed by FabG, FabA/FabZ, FabI, and FabB/FabF
to yield straight long-chain acyl-ACPs for lipid biosynthesis. Straight long-chain acyl-ACP can be
hydrolyzed by the overexpression of a cytosolic thioesterase to produce SCFAs [39]. Mediumchain FAs (C8-C12), which are preferred for biodiesel, can be produced in E. coli by
overexpressing a medium-chain-specific thioesterase [40] (Figure 1-3, Chain-Length Control
Module). Similarly, the S. cerevisiae FASI has been engineered to produce medium-chain FAs at
a titer of 464 mg/L using a rational protein engineering strategy [41]. These medium-chain FAs
can then be derived using engineered conversion pathways to alkanes [42], alcohols [43], and
esters [44] for various applications (Figure 1-3, α-Terminal Structure Control Module).

8

Figure 1- 3 Pathways for the production of fatty acid-derived chemicals
Native E. coli fatty acid pathway is colored grey. The chain length control module is colored purple.
The α-terminal structure control is colored blue. FabH: β-keto-acyl-ACP synthase III; FabB: βketo-acyl-ACP synthase I; FabG: β-keto-acyl-ACP reductase; FabZ: β-hydroxyacyl-ACP
dehydratase; FabI: enoyl-acyl-ACP reductase; FadD: acyl-CoA synthase; ACR: acyl-CoA
reductase; AtfA: wax-ester synthase; AAR: acyl-ACP reductase; ADO: aldehyde decarbonylase;
ADH: alcohol dehydrogenase; FAR: fatty acyl reductase.

Several engineering efforts have been developed to overproduce SCFAs in engineered E. coli
including overexpression of various thioesterases [45, 46], deletion of genes involved in βoxidation (fadD or fadE) [45, 47], engineering global regulators of fatty acid pathways [48], and
implementing synthetic control systems to dynamically control the expression of pathway genes
[13, 14]. Through these efforts, SCFAs have been produced in both high titers and yields [14].
Overall, the highly efficient natural FAS pathways make fatty acid an attractive intermediate
for various chemical productions. On the other hand, the essentiality of fatty acid presents
challenges to engineering: 1) incorporating non-native fatty acids into the cell membrane may
change the membrane fluidity, inhibiting cell growth, 2) expressing native fatty acid biosynthetic
genes is often growth-associated, limiting the production to the growth phase, and 3) interaction
9

between natural FAS enzymes may prevent short- and medium-chain acyl-ACPs from interacting
with desired heterologous enzymes in biosynthetic pathways.

1.5 Scope of this research
Current engineering efforts on E. coli fatty acid biosynthetic pathway only produce straight
chain products, which limits its range of application. On the other hand, chemicals derived from
non-natural fatty acids (NNFAs) have broad applications. For example, branched-chain-fatty-acidderived hydrocarbons have better fuel combustion properties, and ω-hydroxy acids and di-acids
are monomer starting points for producing polymers. Ideally, diversifying the structure of
biosynthesized fatty acids from E. coli could produce non-natural molecules that have exactly the
same chemical structures as petroleum-derived chemicals, and the high rate machinery of E. coli
fatty acid synthesis will facilitate the broad application of these FA-derived compounds.
This dissertation aims to engineer E. coli metabolic pathways to produce NNFAs and their
derivatives. Specifically, I aim to start engineering an E. coli strain to produce branched-chain
fatty acids (BCFAs) in Chapter 2. Then I apply the engineered platform to produce branched-chain
hydrocarbons and to develop strategies to optimize pathway robustness, efficiencies, and yields in
Chapter 3. Finally, I aim to extend the diversity of biologically synthesized fatty acids by testing
the capacity of the fatty acid biosynthetic pathway to incorporate functional terminal groups based
on my engineered pathways in Chapter 4 and Chapter 5. Successful completion of this study will
generate a series of pathways for the biosynthesis of NNFA-derived products, which cannot be
currently produced from renewable resources. Furthermore, the modular-controlled production
system will allow the fine tuning of chemical structures and compositions, making it suitable for
a variety of applications.
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Chapter 2: Engineer an E. coli strain to
produce branched-chain fatty acids in high
percentage
2.1 Introduction
Engineering microbial metabolic pathways allows the production of advanced biofuel and
biochemical with desired structures and properties. Among them, the fatty acid biosynthetic
pathway is particularly attractive because fatty acids are common precursors that can be readily
converted to several types of chemicals including alkanes [42, 49], alkenes [50], alcohols [39, 51],
and esters [52-54] through either biological [55] or chemical conversion [45]. However, the
majority of previous engineering efforts have focused on microbial production of straight-chain
fatty acids (SCFAs) and their derivatives, which have limited cold-flow properties and thus can be
only used during warm weather [56, 57]. The low-temperature operability of fatty acid-derived
fuels can be improved by introducing branches to the fuel molecule, which requires the synthesis
of branched-chain fatty acids (BCFAs) [58].
Naturally, E. coli synthesizes only SCFAs through the multi-enzyme fatty acid type II
biosynthesis system (FASII). The initiation step is catalyzed by the only β-keto-acyl-ACP
synthetase III (FabH, encoded by fabH), which condenses acetyl-CoA with malonyl-ACP to form
acetoacetyl-ACP. Then the four-carbon acyl chain product is elongated on acyl carrier proteins
(ACPs) through repeated cycles of reactions to yield straight long-chain acyl-ACPs (C14-C18) for
lipid synthesis (Figure 2-1A, blue arrow).
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Figure 2- 1 SCFAs and BCFAs biosynthetic pathways
(A) Incorporation of branch groups (R) to fatty acids is determined by the substrate specificity of
FabH. EcFabH (blue) uses acetyl-CoA as a substrate. Branched-chain-acyl-CoA-specific FabHs
(red) preferentially use branched-chain acyl-CoAs as substrates. (B) BCFAs produced from this
study.
Previous studies have shown that FabH plays a key role for the production BCFAs in some
Gram-positive bacteria. While E. coli FabH (EcFabH) can only take acetyl-CoA, and to a lesser
12

extent, propionyl-CoA as substrates, some FabHs from Gram-positive bacteria such as Bacillus
subtilis, Listeria monocytogenes, and Staphylococcus aureus use branched-chain acyl-CoAs (such
as 2-methylpropanoyl-CoA) as starters [59]. Additionally, branched-chain acyl-CoAs can be
synthesized from α-keto acids by the overexpression of a branched-chain α-keto acid
dehydrogenases (BKD, encoded by the bkd operon) [54, 60-62]. Using such biochemistry, a BCFA
biosynthetic pathway was recently constructed by overexpressing the B. subtilis BKD and FabH2
(BsFabH2) [63] (Figure 2-1A, red arrow). However, the engineered strain only produced a low
fraction of equivalent BCFAs [63]. Instead, a significant proportion of equivalent SCFAs were coproduced, making it extremely difficult to separate the desired BCFAs from the predominant
SCFA products. Thus, it is imperative to increase the proportion of BCFAs in total free fatty acids
(FFAs).
I reasoned that the low BCFA titer and proportion are due to the competition of two FabHs
for the same pool of substrate malonyl-ACP and the higher concentration of acetyl-CoA (substrate
of

EcFabH)

compared to branched-chain acyl-CoAs (substrate of

BsFabH2).

In this chapter, the

acetyl-CoA-specific E. coli FabH was replaced with a branched-chain-acyl-CoA-specific FabH to
direct the carbon flux to the synthesis of BCFAs, enhancing BCFA titer by 81-fold compared to a
strain containing both acetyl-CoA- and branched-chain-acyl-CoA-specific FabHs. Furthermore,
the overexpression of BKD to synthesize branched-chain-acyl-CoA precursors was discovered
toxic to E. coli due to depletion of protein lipoylation capacity. Engineering a complementary
protein lipoylation pathway alleviated the toxicity and improved BCFA production to 276 mg/L
and 85% of total free fatty acids, the highest BCFA titer and percentage to date. Finally, I achieved
fine-tuning of BCFA branch positions by engineering the upstream pathway to control the supply
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of branched-chain acyl-CoAs, eventually producing 181 mg/L BCFAs at 72% of total FFA from
glucose.

2.2 Materials and Methods
2.2.1 Materials and Media
Phusion DNA polymerase was purchased from New England Biolabs (Beverly, MA, USA).
Restriction enzymes, T4 ligase, gel purification kits, and plasmid miniprep kits were purchased
from Thermo Scientific (Waltham, Massachusetts, USA). All primers were synthesized by
Integrated DNA Technologies (Coralville, IA, USA). BCFA standards (Bacterial Acid Methyl
Ester Mix), SCFA standards (GLC-20 and GLC-30) and all the other reagents were purchased
from Sigma Aldrich (St. Louis, MO, USA).
Minimal medium (M9 medium supplemented with 75 mM MOPS at pH 7.4, 2 mM MgSO4,
1 mg/L thiamine, 50 μg/mL lipoic acid, 10 μM FeSO4, 0.1 mM CaCl2 and micronutrients including
3 μM (NH4)6Mo7O24, 0.4 mM boric acid, 30 μM CoCl2, 15 μM CuSO4, 80 μM MnCl2, and 10 μM
ZnSO4) containing 2% glucose as carbon source was used for cell growth and fatty acid production.

2.2.2 Plasmids and strains
Plasmids used in this study were listed in Table 2-1. Gene encoding S. aureus (SaFabH) was
codon-optimized for E. coli expression and synthesized by Integrated DNA Technologies
(Coralville, IA, USA), respectively, whereas other genes were amplified by PCR from templates.
To create all plasmids (Table 3-1), the corresponding genes were assembled into the backbones of
BioBrick plasmids [64], using either restriction sites, Golden-Gate DNA assembly method [65],
or Gibson isothermal assembling method [66].
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Table 2- 1 Plasmids used in Chapter 2
Plasmids
Replication ori
pA5a-tesA
pA15a
pB5c-rfp
pBBR1
pE1k-BsfabH2
ColE1
pB5c-bkd
pBBR1
pB8k-BsfabH2
pBBR1
pE8c-bkd
ColE1
pSa-PecfabH-BsfabH1 SC101
pSa-PecfabH-BsfabH2 SC101
pSa-PecfabH-SafabH
SC101
pB5c-tesA-bkd
pBBR1
pE8c-tesA-bkd

ColE1

pE8k-lplA
pA5k-fadR-lplA
pE8c-tesAmleuABCD
pA6k-alsS-ilvCD

ColE1
pA15a
ColE1
pA15a

Overexpressed operon
P lacUV5-tesA(E.coli)
PlacUV5-rfp
PTrc-fabH2(B.subtilis)
PlacUV5-bkd(B.subtilis)
PBAD-fabH2(B.subtilis)
PBAD-bkd(B.subtilis)
PecfabH-fabH1(B.subtilis)
PecfabH-fabH2(B.subtilis)
PecfabH-fabH (S.aureus)
PlacUV5-tesA(E.coli)bkd(B.subtilis)
PBAD-tesA(E.coli)bkd(B.subtilis)
PBAD-lplA(E. coli)
PlacUV5-fadR-lplA (E. coli)
PBAD-tesA-mleuABCD (E.
coli)
PLlacO-1- alsS-ilvCD (E. coli)

Resistance
AmpR
CmR
KanR
CmR
KanR
CmR
AmpR
AmpR
AmpR
CmR

Refs
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter

CmR

This chapter

KanR
KanR
CmR

This chapter
This chapter
This chapter

KanR

E. coli DH10B was used for cloning purposes. E. coli strains DH1(ΔfadE) and CL111 [67] (a
gift from Dr. John Cronan’s Lab, University of Illinois at Urbana-Champaign) were used for fatty
acid production. Strains BC11-13 were created by transforming the corresponding fabH plasmids
into CL111 followed by deletion of the Salmonella enterica Serovar Typhimurium fabH (SefabH)
using P1 transduction [67]. To created strain BC13(ΔKan), Kan antibiotic marker in the genome
of CL111 strain was deleted using plasmid pCP20 [68]. Plasmid pSa-PecfabH-SafabH was
transformed into the kan deleted CL111 strain and the SefabH was knocked out by P1 transduction.
Strain BC33 was created by integrating the bkd operon (lpdV, bkdAA, bkdAB, and bkdB) at the
fadE locus in the genome under the control of a PLacUV5 promoter using a previously described
technique [69], followed by transforming plasmid pSa-PecfabH-SafabH and knocking out the SefabH
by P1 transduction [67]. The corresponding plasmids were then transformed into different parental
strains to yield all the production strains.
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Table 2- 2 Strains used in Chapter 2
Strains
Relevant genotype
fabH gene
CL111
UB1005, attHK022::(plsX’fabH; aadA) fabH::kan SefabH
BC01
DH1(ΔfadE) pB8k-BsfabH2, pE8c-bkd, pA5aEcfabH BsfabH2
tesA
BC02
DH1(ΔfadE) pE1k-BsfabH2, pB5c-bkd, pA5aEcfabH BsfabH2
tesA
SC01
DH1(ΔfadE) pA5a-tesA
EcfabH
SC02
DH1(ΔfadE) pB5c-rfp, pA5a-tesA
EcfabH
SC03
DH1(ΔfadE) pE8c-tesA-bkd
EcfabH
A
BC11
CL111 (plsX’fabH; aadA)::Tet pSa-PecfabHBsfabH2
BsfabH2
BC12
CL111 (plsX’fabH; aadA)::TetA pSa-PecfabHBsfabH1
BsfabH1
BC13
CL111 (plsX’fabH; aadA)::TetA pSa-PecfabHSafabH
SafabH
BC10A CL111 pSa-PecfabH-BsfabH2 pE8c-tesA-bkd
SefabH BsfabH2
A
BC11A CL111 (plsX’fabH; aadA)::Tet pSa-PecfabHBsfabH2
BsfabH2, pE8c-tesA-bkd
BC12A CL111 (plsX’fabH; aadA)::TetA pSa-PecfabHBsfabH1
BsfabH1, pE8c-tesA-bkd
BC13A CL111 (plsX’fabH; aadA)::TetA pSa-PecfabHSafabH
SafabH, pB5c-tesA-bkd
BC11L
CL111 ((plsX’fabH; aadA)::TetA, △Kan, pSaBsfabH2
PecfabH-BsfabH2, pB5c-tesA-bkd, pE8k-lplA
BC13L
CL111 (plsX’fabH; aadA)::TetA, △Kan, pSaSafabH
PecfabH-SafabH, pB5c-tesA-bkd, pE8k-lplA
BC13FL CL111 (plsX’fabH; aadA)::TetA, △Kan, pSaSafabH
PecfabH-SafabH, pE8c-tesA-bkd, pA5k-fadR-lplA
BC30
CL111(△kan) fadE:: bslpdV-bsbkdAA-bsbkdABSefabH
bsbkdB
BC33
CL111(△kan) (plsX’fabH; aadA)::TetA fadE::
SafabH
bslpdV-bsbkdAA-bsbkdAB-bsbkdB pSa-PecfabHSafabH
BC33C
CL111 (plsX’fabH; aadA)::TetA, △Kan,
SafabH
fadE::bkd, ldhA::fadR-lplA, pSa-PecfabH-SafabH,
pE8c-tesA-mleuABCD, pA6k-alsS-ilvCD

Reference
[67]
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter

2.2.3 Cell culturing and α-keto acids supplementation
Cells were pre-cultivated in LB medium with proper antibiotics. Overnight cultures were
inoculated 2% v/v into M9 minimal medium (described in section 2.2.1) with corresponding
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antibiotics for adaptation. Overnight cultures in minimal medium were then used to inoculate 5
mL of the same fresh minimal medium, with an initial OD600 of 0.08. When OD600 reached 0.8,
cells were induced with proper inducers (1mM isopropyl β-D-1-thiogalactopyranoside (IPTG), 0.4%
arabinose, and/or 200 nM anhydrotetracycline (aTc), or as otherwise specified). For α-keto acid
supplementation experiments, one of the α-keto acids (3-methyl-2-oxobutyric acid, 3-methyl-2oxopentanoic acid, or 4-methyl-2-oxopentanoic acid) was added at OD600 = 0.8 to a final
concentration of 1 g/L. Cells were harvested three days after induction.
Cell growth curves were recorded on an Infinite F200PRO (TECAN) plate reader. Overnight
LB cultures were used to inoculate modified M9 medium with 2% glucose. Overnight cultures
were then used to inoculate 5 mL of the same fresh minimal medium with an initial OD600 of 0.08.
Upon inoculation, 150 μl of the culture was aliquoted into a 96-well plate. The 5 mL culture was
used for fatty acid quantification, while the 96-well plate was incubated inside the plate reader
with shaking (218.3 rpm, 37 °C) to record cell growth. Relative cell density (in arbitrary units)
was measured by monitoring absorption at 600 nm. Data were taken every 1500 s until cell cultures
reached late stationary phase.

2.2.4 qRT-PCR
qRT-PCR was performed using a previously published method [70]. Strains DH1(ΔfadE),
BC13 and BC13A were cultivated as described in section 2.2.3 and induced with 1 mM of IPTG
and the supplementation of 1g/L 4-methyl-2-oxopentanoic acid. Total RNAs were extracted from
exponentially growing cells in duplicate using TRIzol Max Bacterial RNA Isolation Kit (life
technologies). Contaminating DNA was removed with RNase-free DNase I (Thermo Scientific),
and cDNAs were synthesized using a Revert Aid First Strand cDNA Synthesis Kit (Thermo
Scientific) with random hexamer primers following the manufacturer’s protocol. The synthesized
17

cDNAs were normalized to 0.2 μg/μL, and 1 μL was amplified using the Power SYBR Green PCR
Master Mix (Applied Biosystems) and primers specific to the genes of interest in a 20 μL reaction
system. The reaction for each gene in each sample was performed in triplicates. qRT-PCR assays
were carried out on an ABI7500 fast machine with the thermal cycling conditions recommended
by the manufacturer. For data analysis, expression levels of the house keeping gene dnaK were
used as a control for normalization between samples. Fold changes of genes of interest were
calculated as 2-ΔΔCT.

2.2.5 Quantification of the free fatty acids
Titers of free fatty acids were quantified using a previously published method [48].
Specifically, 1 mL of cell culture was acidiﬁed with 100 μL of concentrated HCl (12N). Free fatty
acids were extracted twice with 0.5 mL ethyl acetate, which was spiked with 20 μg/mL of C19:0
fatty acid as an internal standard. The extracted fatty acids were methylated to fatty acid methyl
esters (FAMEs) by adding 10 μL concentrated HCl, 90 μL methanol, and 120 μL of TMSdiazomethane, and incubated at room temperature for 15 min. FAMEs were quantified using a
GC-MS (Hewlett-Packard model 7890A, Agilent Technologies) equipped with a 30 m DB5-MS
column (J&W Scientiﬁc) and a mass spectrometer (5975C, Agilent Technologies) or a FID
(Agilent Technologies) detector. For each sample, the column was equilibrated at 80 °C for 1 min,
followed by a ramp to 280 °C at 30°C/min, and was then held at 280 °C for 3 min. Individual
BCFA peaks were identified by comparing their retention time to those of standard BCFA methyl
esters (Bacterial Acid Methyl Ester Mix, Sigma Aldrich) and by comparing their mass spectra to
the Probability Based Matching (PBM) Mass Spectrometry Library. Concentrations of each fatty
acid were determined by comparing the area of each FAME peak to a standard curve generated by
standard FAME mixtures (GLC-20, GLC-30, and Bacterial Acid Methyl Ester Mix, Sigma Aldrich)
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eluted using the same method. BCFA titer for each strain was measured in biological triplicate
(starting from three different colonies) and average values are reported.

2.2.6 Western blotting and protein analysis
Whole culture, volume normalized by optical density at 600 nm, was incubated with loading
buffer (2x Laemmli Sample Buffer (Bio-Rad) and β-mercaptoethanol) at 99oC for 10 minutes with
vigorous shaking. Then, 15 μl of whole culture lysates was loaded onto two 12% polyacrylamide
denaturing gels and separated by electrophoresis. Gels were duplicated and run in parallel. One
gel was then stained with Coomassie blue and the other was immunoblotted. For immunoblotting,
protein was blotted to a polyvinylidine fluoride (PVDF) membrane using a standard protocol
(Gallagher et al., 2008). Lipoate modified enzymes were detected using a rabbit-anti-lipoyl
primary antibody (EMD-Millipore) followed by a goat-anti-rabbit secondary antibody conjugated
to horseradish peroxidase (Santa Cruz Biotechnology). Stained membranes were imaged using a
GE ImageQuant (LAS 4000 mini).

2.3 Results
2.3.1 Construction of BCFA biosynthetic pathway
I first constructed a BCFA biosynthetic pathway similar to previous work [63]. In detail, the
B. subtilis BKD complex (encoded by ipdV, bkdAA, bkdAB and bkdB), BsFabH2, and a cytosolic
E. coli thioesterase TesA (encoded by ‘tesA) were overexpressed in a fadE deleted E. coli DH1
background. The resulting strain (BC01) only produced 0.9% BCFAs at a titer of 2.7 mg/L (Figure
2-2). No significant increase in BCFA titer or proportion was observed even with the enhanced
expression level of

BsFabH2

by changing its promoter from a relative weak (about one third of

expression level compared to standard) PBAD (induced with 0.4% arabinose in the presence of 2%
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glucose in the medium) to a very strong (about 4 times of expression level compared to standard)
Ptrc (induced with 1 mM of IPTG) [64] (from 2.7 mg/L, 0.9% in BC01 to 3.5 mg/L, 1.9% in BC02,
Figure 2-2). In both cases, SCFAs were the dominant products (Supplementary Figure 2-1A). The
low BCFA proportion is consistent with previous studies [63, 71].

2.3.2 Replacement of EcFabH with branched-chain-specific FabHs
The key enzyme for the production of SCFA v.s. BCFAs is FabH, which catalyzes the
condensation of malonyl-ACP and acetyl-CoA in the case of SCFAs or the condensation of
malonyl-ACP and a branched-chain acyl-CoA in the case of BCFAs. Overexpression of BsFabH2
in previously engineered E. coli strains resulted in two FabHs competing for malonyl-ACP [63,
71]. In these strains, the EcFabH may outcompete BsFabH2 because the specific activity of EcFabH
to acetyl-CoA is 3-6 folds higher than the activity of BsFabH2 to branched-chain acyl-CoAs based
on in vitro characterization [59]. Furthermore, acetyl-CoA is abundant in E. coli (0.61 mM) [72],
but it is difficult to accumulate branched-chain acyl-CoAs to concentrations close to or higher than
acetyl-CoA. As a result, SCFAs were produced predominantly (>98%) even when
overexpressed from a strong promoter.
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α-keto acid supply
α-keto acid
synthetic pathway

Figure 2- 2 BCFA titers produced by engineered E. coli strains in this study
EcFabH, SeFabH, BsFabH2, and SaFabH are FabHs from E. coli, S. enterica, B. subtilis, and S. aureus,
respectively. Cells were cultivated as described in Method. BCFA titers from biological triplicate
were averaged. Numbers above the column indicate the proportions of BCFA over total FFA
production.
I hypothesized that deletion of

EcFabH

attenuate the synthesis of SCFAs. Although

(complete replacement of
BcFabH2

EcFabH

by

BsFabH2)

will

also recognizes acetyl-CoA as a substrate,

its specific activity to acetyl-CoA is 24% and 30% lower than that to 2-methylpropanoyl-CoA and
3-methylbutyryl-CoA, respectively [59]. However, direct replacement of EcFabH with a branchedchain-acyl-CoA-specific FabH is technically challenging because 1) fabH is essential for fatty acid
biosynthesis [67], and 2) it is the second gene in a fab operon that contains several essential genes
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in E. coli fatty acid biosynthesis [73]. To solve this problem, I used a previously engineered E. coli
strain (CL111) [67], whose fabH was already replaced by an acetyl-CoA-specific S. enterica fabH
(with similar activity with EcFabH) at the attHK022 phage attachment site [67]. I cloned the B. subtilis
fabH2 (BsfabH2) 3’ of the E. coli fabH promoter (PecfabH) to a low copy number plasmid (SC101
ori) and transformed the resulting plasmid pSa-PecfabH-BsfabH2 to CL111, leading to strain BC10
that have both SefabH and BsfabH2 genes (Table 2-2). The SefabH in BC10 was then removed by a
genetic manipulation that involved P1 transduction of a Tn10 transposon near the attHK022
attachment site to yield strain BC11 that contained BsfabH2 as the only fabH gene. Both BC10 and
BC11 were transformed with a plasmid encoding BKD and TesA (pE8c-tesA-bkd), resulting in
strains BC10A and BC11A, respectively. When cultivated under the same condition, strain BC11A
produced 17.5 mg/L of BCFAs, which is 35-fold higher than the strain with both
BsfabH2

SefabH

and

(BC10A, 0.5 mg/L, Figure 2-2). The BCFA proportion was also increased to 11%, 43-

fold higher than that of BC10A.
I then used the fabH replacement method to test two more FabHs (BsFabH1, SaFabH), whose
specificity to branched-chain acyl-CoAs are even higher than

BsFabH2

[59, 74]. Strain BC12A

expressing BsFabH1 (encoded by BsfabH1 gene), BKD, and TesA produced 19.4 mg/L of BCFAs,
representing 39-fold increase as compared to BC10A. More interestingly, strain BC13A
expressing SaFabH (encoded by SafabH gene), BKD, and TesA produced 40.3 mg/L of BCFAs,
corresponding to 81-fold enhancement from BC10A (Figure 2-2). Even compared to strain BC01
which cannot undergo β-oxidation, the BCFA titer of strain BC13A is 15-fold higher. The
proportion of BCFAs was also increased to 29% and 27% in strains BC12A and BC13A,
respectively. In general, the engineered strains produced a variety of BCFAs with chain length
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spanning from C13 to C17 and carrying different terminal structures (iso and anteiso) (Figure 21B).

Figure 2- 3 Effects of FabH replacement on BCFA production
Cells were cultivated as described in Methods. BC10A-BC12A were induced with 0.4% arabinose
while BC13A was induced with 1 mM IPTG.
Next, BCFA profiles of these strains were analyzed. Although strains BC11A-BC13A
expressing different FabHs, their BCFA profiles are similar: C15:0-anteiso-FA is the most
abundant BCFA following by either C15:0-iso- or C16:0-iso-FA (Figure 2-3). However, in vitro
characterization of these FabHs showed different preference towards acyl-CoA substrates [74].
For example, the activity of

BsFabH1

to 2-methylbutyryl-CoA was 10-fold higher than 3-

methylbutyryl-CoA, whereas the activity of

BsFabH2

was 2-fold higher than that to 3-

methylbutyryl-CoA [59]. The inconsistency between the in vitro FabH specificities and in vivo
BCFA profiles strongly indicated that BCFA production in the engineered strains was limited by
the branched-chain acyl-CoAs supply.
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2.3.3 Supplementation of α-keto acids
In the engineered strains, branched-chain acyl-CoAs are biosynthesized by BKD from
branched-chain α-keto acids (3-methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, and 3methyl-2-oxopentanoic acid), which are naturally produced as precursors for the biosynthesis of
valine, leucine and isoleucine, respectively. The intracellular α-keto acids pool might be limited
because biosynthesis of branched amino acids is heavily feedback regulated in E. coli [75-77].
Thus, it is possible that the production of BCFAs was limited by the supply of branched-chain αketo acids. To test these hypotheses, I supplemented each of the following α-keto acids: 3-methyl2-oxobutyric acid (converted 2-methylpropanoyl-CoA), 4-methyl-2-oxopentanoic acid (converted
3-methylbutyryl-CoA), and 3-methyl-2-oxopentanoic acid (converted 2-methylbutyryl-CoA), to
strains BC11A-BC13A and tested their BCFA productions.
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Figure 2- 4 Effect of α-keto acid supplementation to BCFA productions
Strain BC13A (containing SaFabH) was cultivated as described in Methods and induced with 1
mM of IPTG. At the moment of induction, cell cultures were supplemented with 1 g/L of either 3methyl-2-oxobutyric acid (A, solid columns), 4-methyl-2-oxopentanoic acid (B, solid columns),
3-methyl-2-oxopentanoic acid (C, solid columns), or nothing (A-C, empty columns). (D) BC13A
cell cultures were titrated with varied IPTG concentrations.
Supplementation of 1 g/L of 3-methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, and
3-methyl-2-oxopentanoic acid to strains BC11-13A significantly enhanced the production of evenchain-iso-FAs, odd-chain-iso-FAs, and odd-chain-anteiso-FAs, respectively (Figure 2-4&5,
Supplementary Figure 2-2&3), confirming that supply of branched-chain acyl-CoAs (more
specifically, α-keto acids) limited the synthesis of BCFAs. The specific enhancement also
confirmed that BCFAs were produced through the designed pathways. Interestingly, I observed
that supplementation of each α-keto acid also inhibited the production of BCFAs derived from the
other two α-keto acids (Figure 2-4, Supplementary Figure 2-2&3), presumably due to the
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competition of α-keto acids for available BKD activity. These results indicated that the conversion
of α-keto acids to branched-chain acyl-CoAs is a rate-limiting step for the engineered strains when
supplied with 1 g/L of α-keto acids. The cross-inhibition also demonstrated that the composition
of BCFAs can be controlled by the supply of α-keto acids. For example, when 4-methyl-2oxopentanoic acid was supplemented to the culture of BC13A (carrying SaFabH), odd-chain-isoFAs were produced as the predominant BCFAs (95%, Figure 2-4B). On the other hand, when 3methyl-2-oxopentanoic acid was supplemented to the culture of BC13A, odd-chain-anteiso-FAs
were produced as the predominant BCFAs (>99%, Figure 2-4C). Among the tested conditions,
supplementing 4-methyl-2-oxopenoate to BC13A produced the highest BCFA titer, 93 mg/L, and
the highest BCFA proportion, 43% (Figure 2-5).

Figure 2- 5 Total BCFA titers (A) and proportions (B) for strains BC11-13A with and without
α-keto acid supplementation.
Next, the transcriptional responses to the replacement of E. coli native fabH with other fabHs
was investigated. The transcription levels of fabD and fabG, two downstream genes in the fab
operon, were analyzed by qRT-PCR (Figure 2-6). Compared to the wide type strain DH1 (ΔfadE),
the transcription levels of both fabD and fabG were lower in strain BC13 and BC13A, suggesting
that the fabH replacement affected the transcription of downstream genes. This might give some
explanation for the relatively low total fatty acid production in the engineered strain. However, the
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expression level of fabD increased in strain BC13A compared to that in strain BC13 (Figure 2-6),
likely results from the overexpression of tesA. Because the increased acyl-CoA concentration due
to the accumulation free fatty acids will help activate FadR expression, which can further activate
the PfabH promoter.

fabD

fabG

mRNA fold change

0

-3

-6

-9

BC13

BC13A

Figure 2- 6 Fold changes of transcription levels of fabD and fabG in strain BC13 and BC13A
compared to wide type strain DH1(ΔfadE)

2.3.4 Heterologous BKD expression restricts lipoylation of E. coli native 2-

oxoacid dehydrogenases
I further titrated the culture of BC13A with varying concentrations of inducer IPTG to find
the optimal expression level for TesA and BKD. The highest BCFA titer was obtained when 0.1
mM of IPTG was used, yielding 126 mg/L BCFAs, corresponding to 52% of the total FFAs (Figure
2-4D, Supplementary Figure 2-1B). In contrast, induction with 1 mM IPTG caused stress to the
cell and led to modification to the plasmid encoding the BKD and TesA (data not shown).
Next, the impact of BKD and/or TesA overexpression on cell growth and free fatty acid (FFA)
production was elucidated individually. To start with, I constructed a FFA-overproducing strain,
SC01 by overexpressing TesA in DH1 (△fadE). The overexpression of bkd operon was introduced
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to strain SC01, resulting in strain SC03. BKD overexpression significantly reduced cell growth
when compared to strain SC03, p<0.01 (Figure 2-7A). Expression of a red fluorescent protein
(RFP, strain SC02) did not affect cell growth, indicating that the impaired cell growth was likely
not caused by metabolic burden from protein expression. When strains SC01 and SC03 were
cultivated for FFA production, a significant reduction in total FFA occurred with BKD
overexpression, indicating that BKD expression also inhibits total FFA production (Figure 2-7B).

Figure 2- 7 Expression of BKD reduces cell growth and free fatty acid production
(A) Growth of fatty acid-overproducing strains with (SC03) or without (SC01) BKD
overexpression (p<0.01, Student’s T-test). (B) Overexpression of BKD reduced free fatty acid
(FFA) production (p<0.01). Data generated by and figure courtesy of Dr. Gayle Bentley.
In the quest to understand the observed BKD toxicity, I examined the highly conserved OADH
enzyme class. Previous work determined that overexpression of the PDH E2 subunit in E. coli
repressed PDH activity, suggesting that E. coli has limited protein lipoylation capacity [78].
Expression of heterologous BKD requires lipoylation of its E2 subunit, which might similarly
deplete the cellular lipoylation capability, leading to unlipoylated PDH and OGD in addition to
under-lipoylated BKD (Figure 2-8A, Panel ii). Because both PDH and OGD contribute to central
metabolism, I hypothesized that BKD overexpression without expanded lipoylation capacity
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restricts lipoylation of PDH and OGD (Figure 2-8A, ii), resulting in the observed growth defect
and reduced fatty acid production (Figure 2-7).

Figure 2- 8 Expression of BKD reduces lipoylation of native 2-oxoacid dehydrogenases
(OADHs)
(A) Model illustrating the proposed mechanism of BKD toxicity. (i) Native 2-oxoacid
dehydrogenases (OADHs, blue) are lipoylated for proper function. (ii) When BKD (yellow) is
overexpressed, protein lipoylation capability is depleted, leading to unlipoylated OADHs. (iii)
OADHs can be fully lipoylated through the overexpression of LplA, which ligates lipoic acid to
the E2 subunit of each OADH. (B) Top, 12% SDS-PAGE gel stained with Coomassie blue; bottom,
Western Blot of the same samples blotted using an anti-lipoyl monoclonal antibody. Conditions
for each Western sample are listed beneath each lane. Data generated by and figure courtesy of Dr.
Gayle Bentley.
To test my hypothesis, whole cell lysates of strains with (SC03) or without BKD (SC01)
overexpression were analyzed by SDS-PAGE and Western Blot using an anti-lipoyl-protein
monoclonal antibody (Figure 2-8B). Without BKD, I observed lipoylated proteins corresponding
to the molecular weights of the PDH E2 subunit (62 kDa) and the OGD E2 subunit (44 kDa, lane
1 in Figure 2-8B). Strain SC03 with BKD overexpression showed a strong lipoyl-protein band
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corresponding to the size of the BKD E2 subunit (45 kDa, cannot be resolved with the 44 kDa
OGD E2), but the previously visible band of lipoylated-PDH E2 disappeared (Lane 2 in Figure 28B). Overall, this data revealed that BKD overexpression depletes lipoylation of E. coli native
OADHs, leading to impaired cell growth (Figure 2-7A) and reduced FA production (Figure 2-7B).

2.3.5 Engineering a protein lipoylation pathway restores OADH lipoylation,
allowing BCFA production in high percentages
I hypothesized that the protein lipoylation deficiency caused by BKD overexpression could be
overcome by engineering a protein lipoylation pathway. E. coli utilizes two pathways for protein
lipoylation (Figure 2-9). The first pathway synthesizes lipoate de novo, for which an octanoyl
moiety from octanoyl-ACP is transferred to an E2 subunit, followed by insertion of two sulfur
atoms into the octanoyl side chain of an octanolyated E2 subunit, forming a five membered ring
(Figure 2-9, red arrows) [79-82]. Alternatively, exogenous lipoic acid can be ligated directly to an
E2 subunit by lipoyl ligase A (LplA, encoded by lplA) (Figure 2-9, blue arrow) [83-85]. To test
the hypothesis, a strain was engineered to utilize exogenous lipoic acid, in order to maximize the
availability of octanoyl-ACP for fatty acid elongation. The lplA gene was cloned under the control
of a PBAD promoter and transformed to strain BC11A, resulting in strain BC11L. Overexpression
of LplA on a plasmid partially improved PDH lipoylation (Lane 3 in Figure 2-8B). Completing
the lipoylation pathway via lipoic acid supplementation further improved PDH E2 and BKD E2
lipoylation (Lane 4 in Figure 2-8B), demonstrating that the engineered pathway improved
lipoylation of not only PDH, but also BKD and ODH.
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Figure 2- 9 Engineered pathway for the production of high percentage branched-chain fatty
acids (BCFAs) in E. coli
The percentage of BCFA products can be dramatically enhanced by engineering protein
lipoylation, either through an endogenous pathway (overexpression of LipB and LipA) or an
exogenous pathway (LplA overexpression in combination with lipoic acid supplement). Cellular
branched-chain α-ketoacid precursors can be enriched by engineering a branched-chain amino acid
biosynthesis pathway (eg. AlsS, IlvCD, and LeuABCD). Data generated by and figure courtesy of
Dr. Gayle Bentley.
Then I tested whether lipoylation restoration could increase BCFA titer and percentage.
Without lipoic acid supplementation, strain BC11L produced 49 mg/L BCFA, statistically
indistinguishable from its parental strain lacking plasmid LplA (BC11A, Figure 2-10A).
Supplementing lipoic acid in the BC11L culture dramatically improved BCFA production by 4fold, reaching 200 mg/L and 81% compared to 29% BCFA without plasmid LplA (BC11A, Figure
2-10A). BCFA production alone in BC11L surpassed total FFA in the parental strain BC11A,
suggesting that lipoylation additionally improved cellular capacity for fatty acid production,
presumably by improving cell fitness through native OADH lipoylation. Among the produced
BCFAs, odd-chain-iso FAs, 11-methyldodecanoic acid (C13 iso) and 13-methyltetradecanoic acid
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(C15 iso), are the major products, individually representing 34% and 53% of total FFAs,
respectively (Figure 2-10B). Lipoic acid added to a strain lacking LplA (BC11A) did not affect
fatty acid production (data not shown). Furthermore, leaky expression of LplA (without arabinose,
PBAD-lplA) restored BCFA production to the same level as with fully induced LplA, consistent
with its role as a protein-modifying enzyme rather than a metabolic enzyme (data not shown).
Similarly, when SaFabH was used instead of BsFabH2, BCFA production was improved with LplA
overexpression (Strain BC13L; 220 mg/L, 79% BCFA) compared to the parental strain lacking
LplA (Strain BC13A; 126 mg/L, 56% BCFA) (Figure 2-10C&D). Expression of FadR, a global
regulator of fatty acid biosynthesis [48, 86], further increased BCFA production to 276 mg/L and
85% of total FFA (Strain BC13FL, Figure 2-10C&D). Overall, the results demonstrated that
engineering the protein lipoylation pathway promotes native OADH and BKD lipoylation, leading
to enhanced BCFA production and a significant increase in BCFA percentage.
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Figure 2- 10 LplA expression with lipoic acid supplementation increases BCFA production
(A) FFA production from strains expressing BsFabH2 as the sole FabH. Strain BC11A was
modified to overexpress LplA (BC11L) (B) fatty acid species produced by each strain, under the
same condition as the bar in (A). (C), (D) Strains expressing the SaFabH as the sole FabH. Strain
BC13A was engineered to express a plasmid LplA, generating strain BC13L. Expression of FadR
in strain BC13L generates strain BC13FL. All cultures (C), (D) were supplemented with 50 mg/L
lipoic acid. All cultures (A)–(D) were supplemented with 1 g/L 4-methyl-2-oxopentanoate. Data
generated by and figure courtesy of Dr. Gayle Bentley.
I next supplemented different kinds of α-keto acids to tailor the chain structures of produced
BCFAs. The highest performing strain, BC13FL, was cultured and supplemented with 1 g/L 3methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, or 3-methyl-2-oxopentanoic acid.
BCFA production strictly mirrored the branch structure of the supplemented α-ketoacid,
generating even-chain-iso, odd-chain-iso, and odd-chain-anteiso fatty acids as the major products,
respectively (Figure 2-11). Under all conditions, BCFA production exceeded 83% of total FFA.
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Specifically, when supplemented with 4-methyl-2-oxopentanoic acid, 93% of BCFA were oddchain-iso fatty acids. Likewise, when supplemented with 3-methyl-2-oxopentanoic acid or 3methyl-2-oxobutyric acid, 93% and 74% of BCFA produced were odd-chain-anteiso or evenchain-iso fatty acids, respectively.

Figure 2- 11 Production of high percentage even chain iso, odd chain iso, and ante-iso BCFA
species
Strain BC13FL was supplemented with 1 g/L of 4-methyl-2-oxopentanoic acid, 3-methyl-2oxopentanoic acid, or 3-methyl-2-oxobutyric acid, separately. (A) FFA profiles of the strain under
each cultivation condition are shown. (B) Percent of BCFAs corresponding to each branch position
with the corresponding α-ketoacid shown in (A). Data generated by and figure courtesy of Dr.
Gayle Bentley.
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2.3.6 Production of BCFA from glucose
After releasing the lipoylation bottleneck, I attempted to generate BCFA from glucose by
engineering the branched-chain amino acid pathway to enrich for branched-chain α-ketoacid
precursors (Figure 2-9). In order to accommodate additional genes required for the branched-chain
amino acid pathway, several operons were integrated into the genome at strategically selected
integration loci to simultaneously eliminate competing pathways. I first integrated the bkd operon
at the fadE locus to reduce potential metabolic burden caused by BKD overexpression and to
prevent potential BCFA consumption in β-oxidation. Next, a synthetic operon containing fadRlplA was integrated at the ldhA locus to direct flux away from D-lactate production. Meanwhile,
the B. subtilis alsS and the E. coli ilvCD gene clusters were expressed to convert pyruvate to 3methyl-2-oxobutyric acid (Figure 2-9). An engineered E. coli leuABCD operon carrying a
feedback-resistant leuA was expressed together with tesA to convert 3-methyl-2-oxobutyric acid
to 4-methyl-2-oxopentanoic acid [87]. Overall, the resulting strain BC33L overexpressed 15
enzymes and produced 181 mg/L BCFAs from glucose, comprising 71% of total FFA (Figure 212A&B). As expected, 13-methyl-tetradecanoic acid (C15 iso) was the major FA species (72% of
the BCFA) due to the accumulation of 4-methyl-2-oxopentanoic acid.
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Figure 2- 12 Production of BCFA from glucose
Strain BC33C contains an engineered 4-methyl-2-oxopentanoic acid-producing pathway to
generate BCFA from glucose (A) Percent composition of straight chain fatty acid (SCFA) and
BCFA of strain BC33C (B) Free fatty acid species produced by strain BC33 from glucose. Data
generated by and figure courtesy of Dr. Gayle Bentley.

2.4 Discussion
Previously, several groups attempted to engineer E. coli to produce BCFAs, but the highest
BCFA percentage was 20% [71], implying a limit to the percentage of BCFA that can be produced
in E. coli, a strictly SCFA-producing organism. In this chapter, I have demonstrated the capability
to engineer E. coli to generate a high percentage of BCFA. By the deletion of E. coli native fabH,
I have increased the BCFA proportions (strain BC13A, 52% in the presence of 4-methyl-2oxopentanoic acid) without sacrificing BCFA titers. Furthermore, I demonstrated that incomplete
protein lipoylation restricted previous BCFA production and a high percentage of BCFA (85% of
total FFA) can be produced in E. coli by engineering its protein lipoylation pathway. Production
of a high proportion of BCFA is key to improve the property of FA-derived fuels because
separation of BCFAs from SCFAs represents significant technical challenges. These approaches
provide a complementary strategy to other engineering efforts.
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Furthermore, while branched-chain-acyl-CoA-specific FabH is essential for incorporating
branches to FAs, I found its overexpression in the presence of

EcFabH

did not increase BCFA

production (strain BC02 compared to BC01). In fact, when

BsFabH2

expression level was

increased by changing from a medium strength promoter (PBAD in the presence of 0.4% arabinose
and 2% glucose) to a strong promoter (Ptrc induced with 1 mM IPTG), total FFA titer decreased
(from 284 mg/L to 183 mg/L). This observation is consistent with previous findings where FabH
at concentrations higher than other FASII enzymes inhibited fatty acid production from an in vitro
reconstructed FASII [88]. Similar inhibition of total FA production by BsFabH2 was also observed
during the development of strain JBEI-7802. Although FASII enzymes are expressed as separate
polypeptide chains, effects of relative protein concentrations to FA production suggests interaction
between FASII proteins, probably in a fashion similar to the integrated type I FAS. Optimizing the
expression level of branched-chain-acyl-CoA-specific FabHs might alleviate such inhibition,
further enhancing BCFA production.

2.5 Conclusion
In general, I have demonstrated that replacing the acetyl-CoA-specific FabH with one of the
three tested branched-chain-acyl-CoA-specific FabHs increased the titer of BCFAs up to 81-fold
relative to the strain containing both FabHs and engineering a protein lipoylation pathway restored
protein lipoylation and further increased the biosynthesis of BCFA. Moreover, even-chain-iso,
odd-chain-iso, and odd-chain-anteiso fatty acids can be separately produced by supplying 3methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, and 3-methyl-2-oxopentanoic acid to
growth media, respectively, indicating the capability to control the terminal group of FAs.
Engineering the 4-methyl-2-oxobutyric acid biosynthetic pathway allowed producing oddchain-iso fatty acids at up to 181 mg/L, and BCFA percentage up to 79% from glucose. As BCFAs
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are important precursors for the production of biofuels with improved cold flow properties, the
method to increase BCFA production by replacing EcFabH and engineering a protein lipoylation
pathway should open new venues for efficient production of advanced biofuels derived from
BCFAs.
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Supplementary Figure 2-1. Fatty acid production profiles of (A) strain BC01 (containing
EcFabH& BsFabH2) and (B) the top-performing strain, BC13A (containing SaFabH), with the
supplement of 1 g/L 4-methyl-2-oxopentanoic acid.
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Supplementary Figure 2-2. Effect of α-keto acid supplementation to BCFA productions. Strain
BC11A (containing BsFabH2) was cultivated as described in Methods and induced with 0.4%
arabinose. At the moment of induction, cell cultures were supplemented with 1 g/L of either 3methyl-2-oxobutyric acid (A, solid columns), 4-methyl-2-oxopentanoic acid (B, solid columns),
3-methyl-2-oxopentanoic acid (C, solid columns), or nothing (A-C, empty columns).
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Supplementary Figure 2-3. Effect of α-keto acid supplementation to BCFA productions. Strain
BC12A (containing BsFabH1) was cultivated as described in Methods and induced with 0.4%
arabinose. At the moment of induction, cell cultures were supplemented with 1 g/L of either 3methyl-2-oxobutyric acid (A, solid columns), 4-methyl-2-oxopentanoic acid (B, solid columns),
3-methyl-2-oxopentanoic acid (C, solid columns), or nothing (A-C, empty columns).
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Chapter 3: Modular pathway engineering for
the production of branched-chain fatty
alcohols
3.1 Introduction
Finite energy resources and increased environmental concerns demand the development of
sustainable and renewable approaches to the production of fuels, chemicals, and materials.
Engineering microbial metabolic pathways to synthesize desired products is an attractive approach.
With recent advances in genetic techniques and metabolic engineering methodologies, various
engineered microbes have been developed to produce an array of chemicals derived from
inexpensive and renewable substrates [55, 89] . Target molecules are typically designed to replace
or mimic those obtained from petroleum or other non-renewable sources [90, 91]. Among these
chemicals, long-chain fatty alcohols (LCFLs) in the range of C12 to C18 have numerous
applications as fuels, emollients, plasticizers, thickeners, and detergents [92-94]. At the industrial
scale, LCFLs are currently produced either through hydrogenation of pretreated natural fats and
oils (oleochemicals) or hydroformylation of petrochemicals (e.g. crude oil, natural gas) [43, 95,
96]. Because both processes require harsh reaction conditions and release harmful byproducts to
the environment [97], microbial production of fatty alcohols from renewable sugars is a promising
alternative.
LCFLs have been recently biosynthesized from engineered microbes through fatty acid
biosynthetic pathway [43, 92, 97-101]. The majority of previously biosynthesized LCFLs contain
straight aliphatic chains. Straight LCFLs have relatively high freezing points and viscosities
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compared to their branched-chain isomers, thus limiting their low-temperature operability—an
essential feature for industrial emollients, lubricants, detergents, and most especially, diesel fuels
[102, 103]. For example, the most abundant biosynthetically produced LCFL, straight-chain
palmityl alcohol (C16, often called cetyl alcohol), melts at 49.3°C and exists as a solid at room
temperature, making it difficult to use as a lubricant or an aircraft hydraulic fluid [104]. In
comparison, the branched isomer, isocetyl alcohol, is a clear liquid at room temperature (melting
point -30°C) with significantly enhanced fluidity and low-temperature operability, and thus is used
in a number of detergent formulations that require low-temperature operability [105]. Introducing
degrees of unsaturation has been used as an alternative method to improve the fluidity of straightchain molecules [106]. However, these molecules are vulnerable to oxidation and color instability,
both of which do not occur in BLFLs, even at high temperatures and pressures [103]. BLFLs
additionally are ranked low in eye and skin irritation, allowing their use in cosmetics and
fragrances [102]. Given the clear breadth BLFL applications, chemical engineers have developed
methods to synthesize naturally scarce BLFLs [107-109]. BLFLs are currently produced from
straight LCFLs using a multi-step, catalytic process that requires high temperature (180-300°C),
strong acids/bases, and multiple operation unites, and the conversion process is unpredictable
[102]. Recently, branched-short-chain alcohols in the range of (C3 to C7) were produced by
engineered microbes [26, 110] as gasoline replacements. However, due to their short chain-length
and high volatility, branched-short-chain alcohols are not suitable for the above-mentioned
applications. Given BLFLs’ lack of natural abundance, their complex synthesis process, and the
demand for their distinctive properties, it is imperative to develop biosynthetic approaches to
produce BLFLs from renewable feedstock.
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Figure 3- 1 Biosynthetic pathways for BLFL production
α-Keto Acid Generation Module (Module A) converts pyruvate to α-keto acid: 3-methyl-2oxobutyric acid or 4-methyl-2-oxopentanoic acid. Acyl-ACP Generation Module (Module B)
incorporates α-keto acid to the fatty acid biosynthetic pathway. Alcohol Formation Module
(Module C) converts branched-chain acyl-ACPs to BLFLs.

Since straight LCFLs have been biologically or chemically derived from free fatty acid
precursors [111], BLFLs theoretically can be derived from branched-chain fatty acids (BCFAs).
BCFAs have been recently biosynthesized in engineered E. coli by overexpressing a heterologous
branched-chain α-keto acid dehydrogenase complex (BKD), a branched-chain-acyl-CoA-specific
β-ketoacyl-acyl-carrier protein (FabH) and a thioesterase (TesA) [112, 113]. This system
ultimately produced BCFA in high percentages from glucose (181 mg/L and 80% BCFA) by
engineering a protein lipoylation pathway and an α-keto acid biosynthetic pathway. However,
highly efficient conversion of BCFAs to BLFLs has not been explored. It was not known whether
the branched-chain intermediates, such as branched long-chain acyl-ACPs, BCFAs, and branched
long-chain acyl-CoAs, are compatible with alcohol-conversion enzymes, even though some
46

enzymes have activities towards branched short-chain-ACP or CoA intermediates [114, 115].
Furthermore, because the BLFL pathway involves in multiple untested reaction, balancing
activities of each sub-pathway to prevent accumulation of branched-chain intermediate is
necessary to obtain high titer and yield [116-119].
To achieve these goals, I constructed and tested four metabolic pathways that convert
branched-chain acyl-ACPs to BLFLs. To optimize productivity, the entire BLFL pathway was
divided into three modules (Figure 3-1): an α-Keto Acid Synthesis Module that converts glucose
to α-keto acids, an Acyl-ACP Generation Module that converts α-keto acids to branched-chain
acyl-ACPs, and an Alcohol Formation Module that converts branched-chain acyl-ACPs to final
branched-chain products. To begin, I experimentally determined the most efficient enzyme
combinations to convert branched-chain acyl-ACPs to BLFLs using an engineered
branched-chain-acyl-ACP-producing basal strain (BC33). This initial pathway identification
allowed us to ascertain whether BLFL production was even feasible, given the available enzymes.
Next, I optimized each module separately and later the entire pathway collectively to produce
even-chain-iso and odd-chain-iso fatty alcohols from glucose. This modular approach enabled the
isolation of each module for testing and optimization, without confounding the system by
simultaneously engineering the other modules.

3.2 Materials and Methods
3.2.1 Materials and Media
Phusion DNA polymerase was purchased from New England Biolabs (Beverly, MA, USA).
Restriction enzymes, T4 ligase, gel purification kits, and plasmid miniprep kits were purchased
from Thermo Fisher Scientific (Waltham, Massachusetts, USA). All primers were synthesized by
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Integrated DNA Technologies (Coralville, IA, USA). BCFA standards (Bacterial Acid Methyl
Ester Mix), SCFA standards (GLC-20 and GLC-30), and all the other reagents were purchased
from Sigma Aldrich (St. Louis, MO, USA).
Minimal medium (M9 medium supplemented with 75 mM MOPS at pH 7.4, 2 mM MgSO4,
1 mg/L thiamine, 50 μg/mL lipoic acid, 10 μM FeSO4, 0.1 mM CaCl2, and micronutrients,
including 3 μM (NH4)6Mo7O24, 0.4 mM boric acid, 30 μM CoCl2, 15 μM CuSO4, 80 μM MnCl2,
and 10 μM ZnSO4) containing 2% glucose and 0.5% yeast extract as carbon sources was used for
cell growth and fatty alcohol production.

3.2.2 Plasmids and strains
Plasmids used in this study were listed in Table 3-1. Genes encoding S. elongatus AAR (aar),
M. marinum CAR (car), and B. subtilis Sfp (sfp) were codon-optimized for E. coli expression and
synthesized by Integrated DNA Technologies (Coralville, IA, USA). Genes encoding ACR
(maqu2507) and Maqu2220 (maqu2220) were amplified by PCR from templates provided by Dr.
Brett M. Barney (University of Minnesota, MN) and Dr. Jay D. Keasling (Joint BioEnergy Institute,
CA). To create all plasmids (Table 3-1), the corresponding genes were assembled into the
backbones of BioBrick plasmids [64], using either restriction sites or Golden-Gate DNA assembly
method [65].
E. coli DH10B was used for cloning purposes. E. coli strain CL111 [67] was used for
production purposes. Strains BO33A-J were created by transforming the corresponding plasmids
(Table 3-2) into BC33 competent cells, respectively. Strain BC43 was created by switching native
leuABCD promoter PleuLp and PleuLp2 to PlacUV5 promoter, using a previously described CRISPRCas9 gene replacement method [120]. Similarly, to create strain BC63, the fadR-lplA operon under
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the control of a PLacUV5 promoter was integrated to the ldhA locus of BC43 strain by the same
CRISPR-Cas9 gene replacement method. Strains BO63V and BO63L were created by
transforming the corresponding plasmids into strain BC63.

3.2.3 Cell culturing and α-keto acids supplementation
Cells were pre-cultivated in LB medium with proper antibiotics. Overnight cultures were
inoculated 2% v/v into M9 minimal medium (described in section 3.2.1) with corresponding
antibiotics for adaptation. Overnight cultures in minimal medium were then used to inoculate 5
mL of the same fresh minimal medium, with an initial OD600 of 0.08. When OD600 reached 0.8,
cells were induced with proper inducers (1mM IPTG, 0.4% arabinose, and/or 200 nM aTc, or as
otherwise specified). For α-keto acid supplementation experiments, one of the α-keto acids (3methyl-2-oxobutyric acid or 4-methyl-2-oxopentanoic acid) was added at OD600 = 0.8 to a final
concentration of 1 g/L. Cells were harvested three days after induction.

3.2.4 Fermentation
Fed-batch fermentation was carried out using a New Brunswick Bioflo 110 fermenter with a
pH meter, a dissolved oxygen electrode, and a temperature electrode. M9 medium (described in
section 2.1, 500 mL) was inoculated with an overnight culture of strain BO63L to an initial OD600
to 0.08, along with appropriate antibiotics and 0.001% Antifoam 204. The fermentation was
initiated with the following settings: Temperature was set to 30 °C, pH was controlled at 7.4 by
automatic feeding of 6N ammonium hydroxide, the airflow rate was kept at 1.5 L/min, and the
average stirring rate was maintained at 500 rpm. Gene expression was induced at OD600 = 10 by
addition of 1 mM IPTG, 0.4% arabinose, and 0.22 μM aTc (final concentration). A glucose stock
solution (400 g/L glucose and 12 g/L MgSO4) was intermittently pulsed into the bioreactor to re-
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supply glucose, and a yeast extract solution (20%) was intermittently added into the bioreactor.
Broth samples (~3 ml) were collected at a series of time points to measure cell density and alcohol
titer.

3.2.5 Quantification of the fatty alcohols
For the quantification of alcohols, 1 mL of cell culture was acidiﬁed with 100 μL of
concentrated HCl (12N). Alcohols were extracted twice with 0.5 mL ethyl acetate, and the organic
layers were isolated. Next, 200 μL of the organic layer from each sample was transferred to one 2
mL clear glass GC vial (Agilent Technologies, Santa Clara, CA), mixed with 200 μL of N,Obis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% v/v chlorotrimethylsilane, and incubated
at 60 °C for 2 h. Alcohol derivatives were quantified using a GC-MS (Hewlett-Packard model
7890A, Agilent Technologies) equipped with a 30 m DB5-MS column (J&W Scientiﬁc) and a
mass spectrometer (5975C, Agilent Technologies) or a FID (Agilent Technologies) detector. For
each sample, the column was equilibrated at 80 °C, followed by a ramp to 300 °C at 20°C/min,
and was then held at 300 °C for 3 min. Individual alcohol peaks were identified by comparing their
retention time to that of a standard (a mixture of 1-tetradecanol, 1-hexadecanol, and 1-octadecanol,
prepared and derivatized identically to samples) and by comparing their mass spectra to the
National Institute of Standards and Technology (NIST) Mass Spectral Library. Concentrations of
each alcohol were determined by comparing the area of each sample peak to a standard curve
generated by standards eluted using the same method. Product titer for each strain was measured
in biological triplicate (starting from three different colonies) and average values are reported.
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Table 3- 1 Plasmids used in Chapter 3
Plasmids
pSa-PecfabH-SafabH
pB5k-aar-lplA
pB5k-sfp-car
pE8c-tesA-lplA
pB5k-maqu2507-lplA
pE5c-tesA-fadD
pB5k-maqu2220
pB5k-maqu2220-lplA
pB5k-adhA
pB5k-yqhD
pB5k-yjgB
pA8c-aar-lplA
pB2k-alsS-ilvCD-yjgB
pE2c-aar-lplA-yjgB
pA6k-alsS-ilvCD
pB2k-alsS-ilvCD
pB5c-aar-lplA-yjgB
pB5c-maqu2220-lplA
pA8c-leuAmutBCD
pE8c-leuAmutBCD
pB5k-maqu2220-leuAmutBCD

Replication ori
SC101
pBBR1
pBBR1
ColE1
pBBR1
ColE1
pBBR1
pBBR1
pBBR1
pBBR1
pBBR1
pA15a
pBBR1
ColE1
pA15a
pBBR1
pBBR1
pBBR1
pA15a
ColE1
pBBR1

pA8c-lplA
pE8c-adhA
pE8c-yqhD
pE8c-yjgB
pE2s-alsS-ilvCD

pA15a
ColE1
ColE1
ColE1
ColE1

Overexpressed operon
PecfabH-SafabH (S. aureus)
PlacUV5-aar(S. elongatus)-lplA(E. coli)
PlacUV5-sfp(B. subtilis)-car(M. marinum)
PBAD-tesA(E. coli)-lplA(E. coli)
PlacUV5-maqu2507(M. aquaeolei VT8)-lplA(E. coli)
PlacUV5-tesA(E. coli)-fadD(E. coli)
PlacUV5-maqu2220(M. aquaeolei VT8)
PlacUV5-maqu2220(M. aquaeolei VT8)-lplA(E. coli)
PlacUV5-adhA(L. lactis)
PlacUV5-yqhD(E. coli)
PlacUV5-yjgB(E. coli)
PBAD-aar(S. elongatus)-lplA(E. coli)
Ptet-alsS(B. subtilis)-ilvCD(E. coli)-yjgB(E. coli)
Ptet-aar(S. elongatus)-lplA(E. coli)-yjgB(E. coli)
PLlacO-alsS(B. subtilis)-ilvCD(E. coli)
Ptet-alsS(B. subtilis)-ilvCD(E. coli)
PlacUV5-aar(S. elongatus)-lplA(E. coli)-yjgB(E. coli)
PlacUV5-maqu2220(M. aquaeolei VT8)-lplA(E. coli)
PBAD-leuAmutBCD(E. coli)
PBAD-leuAmutBCD(E. coli)
PlacUV5-maqu2220(M. aquaeolei VT8)-leuAmutBCD(E.
coli)
PBAD-lplA(E. coli)
PBAD-adhA(L. lactis)
PBAD-yqhD(E. coli)
PBAD-yjgB(E. coli)
Ptet-alsS(B. subtilis)-ilvCD(E. coli)
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Resistance
AmpR
KanR
KanR
CmR
KanR
CmR
KanR
KanR
KanR
KanR
KanR
CmR
KanR
CmR
KanR
KanR
CmR
CmR
CmR
CmR
KanR

Reference
Chapter 2
This chapter
This chapter
This chapter
This chapter
[121]
[121]
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter
[122]
This chapter
This chapter
This chapter
This chapter
This chapter
This chapter

CmR
CmR
CmR
CmR
SpecR

This chapter
This chapter
This chapter
This chapter
This chapter

Table 3- 2 Strains used in Chapter 3
Strains
Parental strains
CL111
CL111(△kan)
BC30
BC33

Relevant genotype

Reference

UB1005, attHK022::(plsX’fabH; aadA) fabH::kan
UB1005, attHK022::(plsX’fabH; aadA), △kan
CL111(△kan) fadE:: bslpdV-bsbkdAA-bsbkdAB-bsbkdB
CL111(△kan) (plsX’fabH; aadA)::TetA fadE:: bslpdVbsbkdAA-bsbkdAB-bsbkdB pSa-PecfabH-SafabH
BC43
BC33 leuO-leuL-leuA::PlacUV5-leuAmut
BC63
BC43 ldhA::fadR-lplA
Alcohol-producing strains
BO33A
BC33 pB5k-aar-lplA
BO33B
BC33 pB5k-sfp-car, pE8c-tesA-lplA
BO33C
BC33 pB5k-maqu2507-lplA, pE5c-tesA-fadD
BO33D
BC33 pB5k-maqu2220-lplA
BO33E1
BC33 pA8c-aar-lplA, pB5k-adhA
BO33E2
BC33 pA8c-aar-lplA, pB5k-yqhD
BO33E3
BC33 pA8c-aar-lplA, pB5k-yjgB
BO33E4
BC33 pE2c-aar-lplA-yjgB
BO33F
BC33 pA8c-aar-lplA, pB2k-alsS-ilvCD-yjgB
BO33F1
BC33, pE2c-aar-lplA-yjgB, pA6k-alsS-ilvCD
BO33F2
BC33, pE2c-aar-lplA-yjgB, pB2k-alsS-ilvCD
BO33F3
BC33, pB5c-aar-lplA-yjgB, pA6k-alsS-ilvCD
BO33G1
BC33, pA8c-leuAmutBCD, pB5k-aar-lplA
BO33G2
BC33, pE8c-leuAmutBCD, pB5k-aar-lplA
BO33H1
BC33 pB5k-maqu2220-lplA, pE8c-adhA
BO33H2
BC33 pB5k-maqu2220-lplA, pE8c-yqhD
BO33H3
BC33 pB5k-maqu2220-lplA, pE8c-yjgB
BO33I1
BC33, pA6k-alsS-ilvCD, pB5c-maqu2220-lplA
BO33I2
BC33, pE2k-alsS-ilvCD, pB5c-maqu2220-lplA
BO33J1
BC33, pA8c-leuAmutBCD, pB5k-maqu2220-lplA
BO33J2
BC33, pA8c-lplA, pB5k-maqu2220-leuAmutBCD
BO43I
BC43 pB5c-maqu2220-lplA, pE2s-alsS-ilvCD
BO63V
BC63 pB5k-maqu2220, pE2s-alsS-ilvCD
BO63L
BC63 pB5k-maqu2220, pE2s-alsS-ilvCD, pA8c-leuABCD
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Chapter 2
Chapter 2
Chapter 2
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

3.3 Results
3.3.1 Engineering Alcohol Formation Modules in BCFA-producing strains
To create the branched-chain-acyl-ACP-producing basal strain BC33, the E. coli fabH was
first replaced by Staphylococcus aureus fabH (SafabH), a modification which was previously
demonstrated to enhance branched-chain fatty acid production [113]. The acyl-CoA
dehydrogenase gene (fadE) was next replaced by Bacillus subtilus bkd, functionally inhibiting βoxidation (ΔfadE) and allowing the activation of branched-chain α-keto acids to branched-chain
acyl-CoAs that can enter the FASII system (ΔfadE::bkd) (Table 3-1 & 2). Next, three Alcohol
Formation Modules were separately constructed in strain BC33 (Table 3-2), resulting in alcoholproducing strains BO33A-C. Strain BO33A utilizes the Synechococcus elongatus acyl-ACP
reductase (AAR, encoded by aar, Figure 3-1) to convert acyl-ACPs to fatty aldehydes [99]. Strain
BO33B first generates FFAs via expression of the E. coli cytosolic thioesterase (TesA), which are
then converted to fatty aldehydes by the Mycobacterium marinum carboxylic acid reductase (CAR,
encoded by car) with Bacillus subtilis Sfp (encoded by sfp) coexpression [92] (Figure 3-1). Strain
BO33C also expresses cytosolic TesA to generate FFAs and overexpresses an E. coli acyl-CoA
synthetase (FadD) to activate FFAs to fatty acyl-CoAs, which are then converted to aldehydes by
overexpressing an acyl-CoA reductase from Marinobacter aquaeolei VT8 (ACR, encoded by
maqu2507) [123] (Figure 3-1). All strains rely on native E. coli alcohol dehydrogenases (ADHs)
to reduce aldehydes to alcohols. The native E. coli lipoyl ligase (encoded by lplA) is also expressed
in all strains to improve the lipoylation of 2-oxoacid dehydrogenases including BKD, which
requires lipoylation to function [112].
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Figure 3- 2 Testing three Alcohol Formation Modules
(a) Overall titer distribution and (b) chain-length of three BLFL-producing strains with different
Alcohol Formation Modules, BO33A-C (Table 3-2). SeAAR, MmCAR, and MaMaqu2507 are
reductases from S. elongatus, M. marinum, and M. aquaeolei VT8, respectively. (c-d) Effect of
alcohol dehydrogenase overexpression on BLFL production. Alcohol profiles of strain BO33A
(without adh overexpression) are compared with those from strain BO33E1 (expressing adhA from
L. lactis), BO33E2 (expressing yqhD from E. coli), and BO33E3 (expressing yjgB from E. coli).
All cultures were supplemented with 1 g/L 4-methyl-2-oxopentanoic acid. Cells were cultivated
and induced as described in Methods.
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I first sought to test the three Alcohol Formation Modules by assessing their capacities to
convert branched-chain acyl-ACPs to BLFLs. Strains BO33A-C were cultivated at previously
determined optimal temperatures for each pathway (See methods) [92, 98, 124] and supplemented
with 1 g/L of 4-methyl-2-oxopentanoic acid, the most favorable α-keto acids for BCFA production
[113]. Each strain produced some BLFLs, representing the first report of BLFL production in E.
coli. The CAR pathway (BO33B) and the ACR pathway (BO33C) produced 28 mg/L and 18 mg/L
BLFLs, respectively. In addition, the chain lengths of the products range from C14 to C18,
consistent with the FFA profile of the TesA-overexpressing strain [39]. Meanwhile, the AAR
pathway (BO33A) produced the highest BLFL titer among these three strains: 54 mg/L,
comprising 84% of the total fatty alcohols (Figure 3-2a). The branch and chain-length profile of
BLFLs produced in BO33A is consistent with the profile of BCFAs produced by strains with
similar genetic backgrounds as previously reported (Figure 3-2b) [112], indicating that the AAR
pathway has little preference between straight-chain and branched-chain acyl-ACP substrates.
Interestingly, the CAR pathway produced 2-fold more straight-chain fatty alcohols but 6-fold less
BLFLs than the AAR pathway, indicating that the CAR pathway is primarily straight-chainspecific. While these results serve as a proof-of-principle that BLFL can be produced at high
percentages in E. coli, the initial low titers indicate that additional engineering efforts are needed
to obtain desirable titers and yields of branched-chain products.
All of the above strains relied upon E. coli native ADHs to convert fatty aldehydes to alcohols.
I next sought to increase BLFL production in strain BO33A by overexpression of ADHs. Three
unique ADHs, adhA from Lactoccocus lactis [122], and yqhD and yjgB [92, 122, 125] from E. coli,
were overexpressed in strain BO33A, resulting in strains BO33E1, BO33E2, and BO33E3,
respectively. When cultivated under the same conditions and with 1 g/L 4-methyl-2-oxopentanoic
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acid, strains BO33E1 and BO33E2 produced 85 and 69 mg/L BLFLs, respectively (Figure 3-2c &
2d). Strain BO33E3 produced 130 mg/L BLFLs, comprising 83% of total alcohols, a 2.4-fold
enhancement over BO33A. Specifically, 73 mg/L of 15-methylhexadecanol and 42 mg/L of 13methyltetradecanol were produced (Figure 3-2c), converting 8% of the supplemented 4-methyl-2oxopentanoic acid and making odd-chain-iso alcohols the major BC alcohol species. Both BO33E1
and BO33E3 had similar fatty alcohol production profiles to that of strain BO33A, indicating that
AdhA and YjgB did not selectively determine chain length or structure. In addition, no aldehyde
was detected in BO33E3 culture, indicating the conversion of aldehyde to alcohol is complete.

3.3.2 Engineering 3-methyl-2-oxobutyric acid Generation Module to produce
even-chain-iso fatty alcohols from glucose
Modular pathway assembly can facilitate step-wise optimizations. With the downstream
Alcohol Formation Module optimized, I next sought to improve the production of BLFL from
glucose by engineering and optimizing the α-Keto Acid Generation Module. In this module, I built
upon the downstream-optimized strain BO33E3 to add the capacity for even-chain-iso fatty
alcohol production from glucose via the precursor 3-methyl-2-oxobutyric acid (Figure 3-3a).
Since the B. subtilis alsS and the E. coli ilvCD have been used to accumulate intracellular 3methyl-2-oxobutyric acid, I first cloned them with yjgB under the control of a strong Ptet promoter
in a medium-copy-number BBR1 origin plasmid (Table 3-1). The resulting plasmid, pB2k-alsSilvCD-yjgB, was co-transformed with pA8c-aar-lplA (aar and lplA under the control of a PBAD
promoter in a pA15a origin plasmid) into strain BC33. Cultivation of the resulting strain BO33F
in the absence of α-keto acid supplementation produced 34 mg/L of BLFLs, comprising 44% of
the total alcohols (Figure 3-3b, Supplementary Figure 3-1). Because the composition of the α-keto
acid determines the final chain structure, the final BLFL composition should mirror the cellular
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pool of α-keto acids. The titer of even-chain-iso BLFLs produced by strain BO33F is 14 mg/L,
lower than the 25 mg/L produced by strain BO33E3 when supplemented with 3-methyl-2oxobutyric acid. It should be noted that the odd-chain-iso BLFLs are elongated from 4-methyl-2oxopentanoic acid, which is generated from 3-methyl-2-oxobutyric acid. The comparable total
BLFL production of these two strains, including both even-chain-iso and odd-chain-iso BLFLs,
indicates that the 3-methyl-2-oxobutyric acid Generation Module was effective, although higher
expression level of this module might generate more even-chain-iso products.
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Figure 3- 3 Balancing three modules to produce even-chain-iso fatty alcohols
Plasmids with different copy numbers and promoters are used to optimize the expression level of
the involved pathways. (a) Biosynthetic pathways for the production of even-chain-iso fatty
alcohols. (b) Titers of even-chain, odd-chain, and total BLFL of engineered strains. Plasmids with
different copy numbers and promoters were employed to bear the involved genes in different
strains. The copy number of the plasmids are defined as low (L), medium (M), and high (H). For
strain BO33E3-4, 1 g/L 3-methyl-2-oxobutyric acid was supplemented.
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3.3.3 Optimizing 4-methyl-2-oxopentanoic acid Generation Module to produce
odd-chain-iso fatty alcohols
In E. coli, the leuABCD operon converts 3-methyl-2-oxobutyric acid to 4-methyl-2oxopentanoic acid, which is the precursor for odd-chain-iso BLFL biosynthesis. Previous work
demonstrated that the ribosome binding sequence (RBS) of native leuA results in weak translation
initiation, and leuA is heavily negatively auto-regulated by free leucine synthesized from 4-methyl2-oxopentanoic acid [87] (Figure 3-4a). In this study, I engineered a mutant operon leuAmutBCD
that

contained

a

feedback-resistant

leuA

[87]

and

a

strong

synthetic

RBS(TTTAAGAAGGAGATATACAT). The leuAmutBCD was cloned in either a low (pA15a) or
a high (pColE1) copy number plasmid to create two engineered strains, BO33G1 and BO33G2,
respectively. To test the conversion efficiency of the leuAmutBCD operon, both strains were
supplemented with 3-methyl-2-oxobutyric acid (the substrate for LeuABCD, Figure 3-4a) during
cultivation. Fully functional leuAmutBCD would result in odd-chain-iso BLFL compositions in a
similar ratio to the previous best-performing strain (strain BO33A) when supplemented with 4methyl-2-oxopentanoic acid. Strain BO33G1 produced 50 mg/L total BLFL and 47 mg/L oddchain-iso fatty alcohol, statistically indistinguishable from the BLFL titer of strain BO33A
supplemented with 4-methyl-2-oxopentanoic acid (Figure 3-4b, Supplementary Figure 3-2). Strain
BO33G1 generated 94% odd-chain-iso fatty alcohol, indicating complete conversion of 3-methyl2-oxobutyric acid by the modified LeuAmutBCD. Conversely, when leuAmutBCD was expressed
under the high copy number plasmid (strain BO33G2), the BLFL titers decreased (p = 0.07) and
had large standard variations (Figure 3-4b), even when the inducer concentration was reduced.
Furthermore, overexpression of leuAmutBCD from the high-copy number plasmid also decreased
cell growth rate and cell density (Data not shown). These results indicate that expression of the
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leuAmutBCD operon at too high a level affects cell growth and BLFL production, thus needs to be
avoided.

Figure 3- 4 Optimizing the 4-methyl-2-oxopentanoic acid Generation Module to produce
odd-chain-iso fatty alcohols
(A) Biosynthetic pathways for the production of odd-chain-iso fatty alcohols. (B) Titers of
engineered odd-chain-iso BLFL-producing strains. Strains BO33G1-2 containing leuAmutBCD in
plasmids with different copy numbers were cultivated as described in Methods and supplemented
with 1 g/L 3-methyl-2-oxobutyric acid. Strain BO33G2 was induced with either 0.1% or 0.4%
arabinose.
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3.3.4 Balancing gene expression levels in all three modules for enhanced BLFL
production from glucose
With the α-Keto Acid Generation and the Alcohol Formation modules optimized separately,
I next sought to balance the gene expression levels within the completed pathway. I selected the
best-performing genetic elements of each individual module to complete the full pathway: the αKeto Acid Generation Module, including alsS & ilvCD, the Acyl-ACP Synthesis Module,
including aar & lplA, and the Alcohol Formation Module, including yjgB (Figure 3-3a). To
perform this optimization, I altered gene copy numbers to change the expression level of each
module. Compatible plasmids with three different copy numbers were used for this purpose: a high
copy number (pColE1, 50 copies per cell), a medium copy number (pBBR1, 17-20 copies per cell),
and a low copy number (pA15a, 7-10 copies per cell) [64] (Figure 3-3b, Supplementary Figure 31). Three additional strains BO33E4, BO33F1, and BO33F2 were created (Figure 3-3b,
Supplementary Figure 3-1). All three strains expressed aar, lplA, and yjgB from the high copy
number plasmids under the control of a very tight promoter (Ptet), but produced less BLFL than
strains BO33E3 and BO33F, which expressed aar, lplA, and yjgB from the low or the medium
copy number plasmid. The low titer is potentially caused by the insolubility of highly
overexpressed AAR [99]. Meanwhile, compared to strain BO33F3 with the low-copy alsS-ilvCD
expression, strain BO33F with the medium-copy alsS-ilvCD expression improved BLFL
production by 3.2-fold. These results suggest that the optimal aar expression level was medium to
low, and that alsS-ilvCD required overexpression in a medium to high-copy number plasmid for
optimal BLFL production (Figure 3-3b, Supplementary Figure 3-1).
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3.3.5 BLFL production from glucose using the acyl-ACP reductase Maqu2220
During the course of this work, Haushalter et al. published the production of straight LCFLs
in high titers by overexpression of a marine acyl-ACP reductase, Maqu2220 from M. aquaeolei
VT8 [121]. Maqu2220 was first characterized as a fatty aldehyde reductase, reducing fatty
aldehydes to fatty alcohols [126]. However, it was later confirmed to have acyl-ACP reductase
activity and is capable of converting acyl-ACPs or acyl-CoAs directly to fatty alcohols [127], thus
significantly simplifying the fatty alcohol pathway. I tested the efficiency of BLFL production via
Maqu2220 by replacing the S. elongatus aar in strain BO33A with maqu2220, resulting in strain
BO33D. When supplemented with 1 g/L of 4-methyl-2-oxopentanoic acid, BO33D produced 198
mg/L (89%) BC alcohols, 3.7-fold higher than that of strain BO33A (Figure 3-5). Even compared
with the previous best-performing strain BO33E3, the BLFL titer of strain BO33D enhanced by
1.5-fold. Most BLFLs (> 99%) were identified in the cell pellet, consistent with previous study
[128]. Moreover, overexpression of the ADHs yjgB, yqhD, or adhA did not enhance BLFL titer
(Figure 3-5), further confirming the previous hypothesis that Maqu2220 contains a catalytic
domain with ADH activity.
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Figure 3- 5 BLFL profiles of engineered E. coli strains containing Maqu2220
While strain BO33D does not contain additional adh, BO33H1-3 overexpressed L. lactis adhA, E.
coli yqhD, and E. coli yjgB, respectively. BLFL profiles are compared with that of strains BO33E3
(the best performing strain in section 3.1). All cultures were supplemented with 1 g/L 4-methyl-2oxopentanoic acid.
After confirming the capability of Maqu2220 to convert branched-chain acyl-ACPs to BLFLs,
I sought to use Maqu2220 to produce BLFLs from glucose by applying the knowledge learned
from optimizing the α-Keto Acid Synthesis Module. After constructing and validating strains, I
found that the optimal expression level of each module mimicked those characterized using the
aar pathway. First, the high-copy number-expression (pColE1) of the alsS-ilvCD operon increased
even-chain-iso fatty alcohol production by 9.2-fold over the low-copy number-expression (pA15a)
(as seen by comparing strains BO33I1 with BO33I2 in Figure 3-6a). Second, when supplemented
with 3-methyl-2-oxobutyric acid, the low-copy number-expression of the leuAmutBCD operon
produced 2.8-fold more odd-chain-iso fatty alcohols than the medium-copy number-expression (as
seen for strains OB33J1 and OB33J2 in Figure 3-6a).
Next, I attempted to combine all three modules to produce BLFLs from glucose, which
requires overexpression of 14 genes from 6 synthetic operons: Ptet-alsS-ilvCD, PBAD-leuAmutBCD,
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PlacUV5-bslpdV-bsbkdAA-bsbkdAB-bsbkdB, PlacUV5-lplA, PecfabH-SafabH, and PlacUV5-maqu2220. To
reduce the burden imposed by multiple plasmids while maintaining a sufficient enzyme expression
level, I tried to integrate some operons into the genome. Based on the findings above, I first created
strain BC43 with a single copy leuAmutBCD from strain BC33. Using the Type II CRISPR-Cas9
system, I replaced the native promoters of the genomic leuABCD operon with the strong IPTGinducible PlacUV5 promoter, and replaced the RBS of leuA (including all regulatory sites) with the
previously-used strong synthetic RBS. Simultaneously, I replaced the leuA-coding gene with the
feedback-resistant leuAmutant. However, when the resulting strain BC43 was transformed with
corresponding plasmids for fermentation, even-chain-iso products predominated over odd-chainiso products (as seen for strains BO43I in Figure 3-6a). This result indicated that the leuAmutBCD
requires very fine-tuning and that a single copy of leuAmutBCD was insufficient to convert all the
intracellular 3-methyl-2-oxobutyric acid to 4-methyl-2-oxopentanoic acid, further proving that
pA15a::PBAD-leuAmutBCD provides optimal expression level for the α-Keto Acid Synthesis
Module. Consistency in expression parameters indicates that the optimal levels derived in this
work may be applicable in other systems requiring the use of an α-keto acid pathway.
Then, I chose lplA as the gene to be integrated into the host cell’s genome; low expression
was previously determined to be sufficient to fully functionalize the BKD E2 subunit [112].
Furthermore, it has been demonstrated that even low-level overexpression of the global regulator
of fatty acid metabolism fadR increases fatty acid production [7, 48]. Thus, fadR was cloned to the
same operon of lplA under the control of the PLacUV5 promoter. The synthetic PLacUV5-fadR-lplA
operon was then integrated into the native ldhA (involved in lactate production) site of strain BC43,
resulting in strain BC63 (Figure 3-6b). Deletion of ldhA was expected to reduce lactate formation
during fermentation [25].
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Strain BC63 was then engineered to produce BLFL with controlled chain structure. To
produce even-chain-iso BLFLs from glucose, I created strain BO63V by co-transforming the
plasmids pB5k-maqu2220 and pE2s-alsS-ilvCD into strain BC63 (Table 3-2, Figure 3-6b). When
fermented in the absence of α-keto acid, BO63V produced 52.4 mg/L of even-chain-iso fatty
alcohols (Figure 3-6a, Supplementary Figure 3-4). To produce odd-chain-iso fatty alcohols from
glucose, the plasmid pA8c-leuAmutBCD was further transformed to strain BO63V (Figure 3-6b).
The resulting strain BO63L produced 122 mg/L of odd-chain-iso BLFLs, comprising 70% of the
total BLFLs (Figure 3-6a, Supplementary Figure 3-4). Although the odd-chain-iso BLFL pathway
is less carbon efficient than the even-chain-iso BLFL pathway due to the loss of a CO2 during 4methyl-2-oxopentanoic acid biosynthesis, the

SaFabH

has higher specificity towards 3-

methylbutyryl-CoA (the precursor for odd-chain-iso products) than 2-methyl-propanoyl-CoA (the
precursor for even-chain-iso products) [113], thus leading to higher odd-chain-iso BLFL titer.
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Figure 3- 6 Optimizing α-keto acid biosynthetic pathways in alcohol-producing strains
containing MaMaqu2220
(a) Plasmids with different copy numbers and promoters were employed to bear the involved genes
in different strains. The titers of even-chain-iso, odd-chain-iso, and total alcohol from all the strains
containing α-keto acid biosynthetic pathways are compared with that of strain BO33D with either
1 g/L 3-methyl-2-oxobutyric acid or 1 g/L 4-methyl-2-oxopentanoic acid supplementation. (b) The
complete pathways and genome modifications involved in strain BC63V (purple) and BC63L
(purple and blue).
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Figure 3- 7 Fed-batch production by strain BO63L
(a) Time-course plots of SCFL and BCFL titer and cell density. (b) BCFL profile at 85 hours
during batch-fed fermentation.
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Finally, I assessed the performance of strain BO63L in a 1 L glucose fed-batch fermenter
(Section 3.2.4). After 85 hours of cultivation, BLFLs accumulated to 350 mg/L (Figure 3-7a). The
concentration of 14-methyl-pentadecanol, the most abundant product, reached 217 mg/L (Figure
3-7b). Interestingly, straight LCFLs accumulated rapidly after induction, while BLFL titers did not
increase until 32 h (Figure 3-7a). I suspect that the initial straight-chain alcohol accumulation may
result from the leaky expression of Maqu2220 prior to induction. Further optimization of
fermentation conditions (such as pH, air flowing rate, stirring rate, etc.) might improve the
percentage and yield of BLFL. Overall, these results demonstrate the potential of strain BO63L
for high-titer production of BLFLs and suggest that further studies might lead to its use on an
industrial scale.

3.4 Discussion
Although alcohol-producing pathways have been previously engineered to produce straight
LCFLs and short-chain alcohols, little effort has been made to produce BLFLs. In this work, I
characterized the capability and substrate specificity of four different alcohol-producing pathways
for BLFL production. I demonstrated the highly selective production of two types of BLFLs (oddchain-iso and even-chain-iso) by engineering the upstream pathways for precursor synthesis. I
obtained high BLFL proportions out of total fatty alcohols (strain BO63L, yielded 80%). I also
obtained comparable BLFL titers (strain BO63L, 175 mg/L in the absence of any precursor) to
BCFA titers, despite the extensive additional engineering required for BLFLs production. The
modular engineering strategy allowed us to apply the knowledge learned from the AAR pathway
to the new identified Maqu2220 pathway for rapid optimization, quickly yielded strain BO63L
that produced 350 mg/L BLFLs in a fed-batch fermenter. Because BLFLs can be directly used in
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skin-care or sunscreen products, and are good candidates for diesel fuels, the production of specific
BLFL species in high percentages may directly benefit the cosmetics and bioenergy fields.
Meanwhile, I partitioned the complete pathway into three modules: a precursor formation
module (the α-Keto Acid Synthesis Module), an acyl-CoA activation and malonyl-ACP
consumption module (the Acyl-ACP Generation Module), and a final product synthesis module
(the Alcohol Formation Module). Each module can be separately engineered and tuned for novel
chemical synthesis. Furthermore, when the tuned modules are combined, the expression level of
each module can be tuned to avoid imbalance and to improve product titer. I demonstrated
consistent expression parameters that result in optimal productivities, which can be used for the
production of other chemicals. Together with previous successes in modular engineering of the
isoprenoid pathway [129], the FFA pathways [46] and the ester pathways [130], I confirm that
modular pathway engineering is an effective approach to improve product titer and yield.
The top-performing strain BO63L produced 350 mg/L BLFLs in fed-batch fermenter, still low
compared to that of the best straight LCFL-producing strain (3.82 g/L in shake flask) [121].
Current pathway is not limited by α-keto acid because increasing the supplemented 4-methyl-2oxopentanoic acid from 1 g/L to 8 g/L did not increase BLFL titer (Supplementary Figure 3-3).
Furthermore, conversion of acyl-ACPs to BLFLs is not likely to be the limiting step due to the
high conversion efficiency of Maqu2220 [121]. Thus, I believe the current bottleneck lies in the
Acyl-ACP Generation Module, which requires further engineering to improve BLFL titer and yield.
Previous engineering strategies developed to optimize free fatty acids production could be
potentially used to further improve BLFL yield. These strategies include modulation of the fatty
acid and the phospholipid biosynthesis pathway [131], implementing synthetic control systems to
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dynamically regulate pathway gene expression [13, 14, 24, 48], and enriching the high-performing
subpopulation using PopQC [24].

3.5 Conclusions
I have constructed and tested the capability of four different alcohol-producing pathways for
BLFL production in engineered E. coli. Moreover, by engineering the α-keto acid biosynthetic
pathways and balancing the expression levels of three different modules, I achieved BLFL titers
of up to 350 mg/L from glucose, and BLFL percentages up to 79%. Overall, this work generates
pathways and knowledge for the production of BLFLs in high percentages that will have broader
industrial applications than straight LCFLs.
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Supplementary Figure 3-1. Fatty alcohol profiles of strains involved in Figure 3-3b.
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Chapter 4: Production of other fatty-acidderived chemicals based on the established
non-natural fatty acid biosynthetic pathway
4.1 Introduction
Increasing concerns about national security and the global petroleum supply have driven the
development of state-of-art technologies for the sustainable production of chemicals, materials,
and fuels that are currently derived from petroleum [132]. Engineering microbes for chemical
production is particularly attractive because it allows the conversion of renewable and low-cost
feedstocks (such as lignocellulosic biomass and CO2) into products with precise structures [55,
133] without the use of high temperatures and pressures. Currently, extensive research focuses on
engineering the fatty acid biosynthetic pathway [134-137], and especially on the efficient
bioconversion of produced fatty acids to other chemicals including alkanes [124], alkenes [50],
alcohols [138], aldehydes [124], and esters [48]. These chemicals can be used as biofuels [55, 138],
pharmaceuticals [139], polymer precursors [140], and lubricants [141].
The biosynthesis of alkanes and esters are of particularly great interest because they are
biofuels with promising physiochemical and combustion properties that are similar to those of
petroleum-based fuels. Like fatty alcohol, fatty acid esters and alkanes can be synthesized from
the same intermediates of the fatty acid synthetic pathway: fatty acyl-ACP or fatty acyl-CoA. Fatty
acid esters have been produced by esterifying acyl-CoA with methanol or ethanol using a wax
ester synthase (AtfA), while alkanes have been generated from fatty aldehyde by aldehydedeformylating oxygenases (ADO) from various origins (Figure 4-1).
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Figure 4- 1 Biosynthetic pathways for alkane and ester production
The Acyl-ACP Generation Module (Module B) incorporates α-keto acid into the fatty acid
biosynthetic pathway. The Product Formation Module (Module C) converts branched-chain acylACPs to alkanes and esters.

Most previously biosynthesized alkanes and fatty acid esters have straight aliphatic chains,
which have relatively higher freezing points than their petroleum-derived, branched-chain
counterparts, limiting their low-temperature operability. Thus, there is much impetus to
biosynthesize fuels derived from branched-chain fatty acids (BCFAs) to such improved properties
as a lower freezing point and better cold flow. In this chapter, I applied the modular engineering
strategy in Chapter 3 to produce branched-chain alkanes and branched-chain fatty acid ethyl esters
(BCFAEEs).
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4.2 Materials and Methods
4.2.1 Materials and Media
Phusion DNA polymerase was purchased from New England Biolabs (Beverly, MA, USA).
Restriction enzymes, T4 ligase, gel purification kits, and plasmid miniprep kits were purchased
from Thermo Fisher Scientific (Waltham, Massachusetts, USA). All primers were synthesized by
Integrated DNA Technologies (Coralville, IA, USA). BCFA standards (Bacterial Acid Methyl
Ester Mix), SCFA standards (GLC-20 and GLC-30), and all the other reagents were purchased
from Sigma Aldrich (St. Louis, MO, USA).
Minimal medium (M9 medium supplemented with 75 mM MOPS at pH 7.4, 2 mM MgSO4,
1 mg/L thiamine, 50 μg/mL lipoic acid, 10 μM FeSO4, 0.1 mM CaCl2, and micronutrients,
including 3 μM (NH4)6Mo7O24, 0.4 mM boric acid, 30 μM CoCl2, 15 μM CuSO4, 80 μM MnCl2,
and 10 μM ZnSO4) containing 2% glucose and 0.5% yeast extract as carbon sources was used for
cell growth and fatty alcohol production.

4.2.2 Plasmids and strains
Plasmids and oligonucleotides used in this study were listed in Table 4-1. Genes encoding
Prochlorococcus merinus ADO (ADO), Alicyclobacillus acidocaldarius FabH (AaFabH), and
Megasphaera elsdenii Pct (Pct) were codon-optimized for E. coli expression and synthesized by
Integrated DNA Technologies (Coralville, IA, USA), whereas other genes were amplified by PCR
and assembled into the backbones of BioBrick plasmids [64] using either restriction sites or
Golden-Gate DNA assembly method [65].
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Table 4- 1 Plasmids used in Chapter 4
Plasmids
Replication ori
Overexpressed operon
Resistance
Refs
R
pB5k-tesA
pBBR1
P lacUV5-tesA(E. coli)
Kan
This study
pE8c-pct
ColE1
PBAD-pct(M. elsdenii)
CmR
This study
R
pSa-PecfabH-AafabH
SC101
PecfabH-fabH (A. acidocaldarius)
Amp
This study
pE5c-fadD-atfA
pBBR1
PlacUV5-fadD(E.coli)-atfA
CmR
This study
R
pE8c-ado
ColE1
PBAD-ado(P. merinu)
Cm
This study
pE8k-lplA
ColE1
PBAD-lplA(E. coli)
KanR
This study
R
pB5k-tesA-lplA
pA15a
PlacUV5-tesA-lplA (E. coli)
Kan
This study

Table 4- 2 Strains used in Chapter 4
Strains
Relevant genotype
CL111
UB1005, attHK022::(plsX’fabH; aadA) fabH::kan
CL111(△Kan) CL111 △kan
BC73
BC63 △yjgB
BC14
CL111(△Kan) pSa-PecfabH-AafabH
BA33A
BC63 pB5k-aar-lplA, pE8c-ado
BA73A
BC73 pA8c-aar-lplA, pB5k-ado
BE33A
BC33 pB5k-tesA-lplA, pE5c-fadD-atfA
BC14A
BC14 pB5k-tesA, pE8c-pct
BO14D
BC14 pB5k-maqu2220, pE8c-pct

Reference
[67]
Chapter 2
This study
This study
This study
This study
This study
This study
This study

E. coli DH10B was used for cloning purposes. E. coli strains CL111 [67] was used for
production purposes. To created strain BC14, plasmid pSa-PecfabH-AafabH was transformed into
CL111(△Kan) strain, and the SefabH was knocked out by P1 transduction [67]. The genomic yjgB
was deleted in BC63 strain using a previously described CRISPR-Cas9 gene replacement method
(Jiang Y. et al. 2015), creating strain BC73. Other strains were created by transforming the
corresponding plasmids (Table 4-2) into corresponding parental strains, respectively.

4.2.3 Cell culturing and α-keto acids supplementation
Overnight cultures were inoculated 2% v/v into M9 minimal medium (in section 4.2.1) with
corresponding antibiotics for adaptation. Overnight cultures in minimal medium were then used to
inoculate 5 mL of the same fresh minimal medium with an initial OD600 of 0.08. Cells were induced
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with proper inducers (1mM IPTG, 0.4% arabinose, and/or 200 nM aTc) when OD600 reached 0.8
or as otherwise specified. For α-keto acids supplementation experiments, one of the α-keto acids
(3-methyl-2-oxobutyric acid, 4-methyl-2-oxopentanoic acid, or glycolic acid) was added at OD600
= 0.8 to a final concentration of 1 g/L. For alkane production experiments, 0.5 mL decane was
added to each sample as an organic layer to extract alkanes. For ester production experiments,
ethanol or isopropanol was added at a final concentration of 5% v/v, respectively. Cells were
harvested three days after induction.

4.2.4 Quantification of the products
For the quantification of diols and fatty acid esters, 1 mL of cell culture was acidiﬁed with
100 μL of concentrated HCl (12N). Diols and esters were extracted twice with 0.5 mL of ethyl
acetate. For derivatization of diols, 200 μL of supernatant from each sample was transferred to 2
mL clear glass GC vials (Agilent Technologies, Santa Clara, CA), mixed with 200 μL of
N,OBis( trimethylsilyl)trifluoroacetamide with 1% v/v chlorotrimethylsilane, and incubated at
60 °C for 2 h. Both diol derivatives and fatty acid esters were quantified using a GC-MS (HewlettPackard model 7890A, Agilent Technologies) equipped with a 30 m DB5-MS column (J&W
Scientiﬁc) and a mass spectrometer (5975C, Agilent Technologies) or a FID (Agilent Technologies)
detector. For each ester sample, the column was equilibrated at 80 °C, followed by a ramp to
280 °C at 30°C/min, and was then held at 280 °C for 3 min. For each diol sample, the column was
equilibrated at 80 °C, followed by a ramp to 300 °C at 20°C/min, and was then held at 300 °C for
3 min. Individual peaks were identified by comparing their retention time to those of diol standards
(mixture of 12-hydroxy-1-dodecanol, 14-hydroxy-1-tetradecanol and 16-hydroxy-1-hexadecanol,
prepared and derivatized identically to samples) or FAEE mixtures (Sigma Aldrich).
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Concentrations of each component were determined by comparing the area of each peak to a
standard curve generated by corresponding standards eluted using the same method.
To quantify alkanes, the decane organic layer was extracted and diluted 10 times. Then the
samples were quantified using a GC-FID (Agilent 6890A) equipped with a 30 m Rtx-1 column
(Restek, Bellefonte, PA). For each sample, the column was equilibrated at 45 °C for 4 min,
followed by a ramp to 300 °C at 15°C/min, and was then held at 300 °C for 5 min. Individual
alkane peaks were identified by comparing their retention time to those of standard alkane
solutions (Sigma Aldrich). Concentrations of each alkane were determined by comparing the area
of each alkane peak to a standard curve generated by standard alkane mixtures eluted using the
same method.
Product titer for each strain was measured in biological triplicate (starting from three different
colonies), and average values are reported.

4.3 Results
4.3.1 Testing alkane-producing pathways in BCFA-producing strains
Based on the optimal expression level for all three Modules in Chapter 3, I expanded the
application of Module (C) for various chemical productions (Figure 3-1). First, I focused on
alkane, another important product derived from the fatty acid synthetic pathway. The alkaneproducing pathway is well-known in cyanobacteria and plants [124, 142]. The key enzyme,
aldehyde-deformylating oxygenase (ADO), has been isolated and characterized to catalyze the
reducing reaction from aldehyde to alkanes. In this chapter, I selected AAR to construct the alkaneproducing pathways, because I suspected that Maqu2220 already contained a subunit functioning
as ADH, which would direct the metabolic flux towards alcohol production. In order to produce
79

branched-chain alkane, the ado gene from Prochlorococcus merinus [143-146] that encodes ADO
was overexpressed in strain BO33A, to generate strain BA33A (Figure 4-1). When cultivated in
37°C without supplementation, strain BA33A produced 8 mg/L total alkane, and 1.7 mg/L
branched-chain alkane. When 4-methyl-2-oxopentanoic acid was supplemented, the BC alkane
titer increased to 10 mg/L, comprising 74% of total alkane production (Figure 4-2) and
representing the highest BC alkane titer and percentage published to date.

Figure 4- 2 Branched-chain alkane production from strain BA33A

Many studies have shown that the deletion of E. coli endogenous alcohol dehydrogenase
increases the aldehyde accumulation and thus improves the alkane production [147, 148]. As
shown in Figure 3-2c, endogenous ADH YjgB has a high specificity toward long-branched-chain
aldehyde, so I deleted the yjgB gene in strain BC63 genome by CRISPR-Cas9, followed by
transforming corresponding plasmids into the resulting strain BC73, hoping the branched-chain
alkane production would improve in the resulting strain, BA73A. However, BA73A produced
similar amounts of alkane regardless of whether α-keto acid was supplemented or not (data not
shown). One possible reason might be that the alkane generation rate of ADO was so slow that the
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deletion of endogenous adhs could not help to redirect the flux towards alkane. Or there are too
many endogenous adhs that could reduce the long-branched-chain aldehyde to alcohols, thus the
deletion of a single adh gene (yjgB) would not decrease the alcohol generation rate. Other strategies,
such as overexpression of fatty alcohol oxidase (FAO) and/or manipulation all the factors related
to fatty aldehyde dynamic pools [149], might further improve the branched-chain alkane
production.

4.3.2 Assembling the ester-producing pathway in BCFA-producing strains
The production of fatty acid ethyl esters (FAEE), the major component of biodiesel, has been
demonstrated in E. coli. However, the microbially-produced FAEE primarily consist of ethylpalmitate, which has a melting point of 23oC, and so is not suitable in cold weather. Alternatively,
ethyl-anteiso-methyl-palmitate does not freeze until the temperature reaches 3.8oC, a much more
amenable temperature for direct usage in a variety of climates, demonstrating the value of
BCFAEEs [150, 151].

Figure 4- 3 Fatty acid ester production from strain BE33A
Data generated by Dr. Gayle Bentley.
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Just as for the BCFL production, I first focused on the Module C to produce BCFAEEs from
BCFAs. Strain BE33A was constructed by transforming the plasmid pB5k-fadD-atfA into BCFAproducing strain BC33A (Table 4-2). Free BCFAs were converted into branched-chain acyl-CoAs
by an acyl-CoA synthase (encoded by fadD) and then transesterified to BCFAEEs by a wax ester
synthase (encoded by atfA). When cultivated with supplementation of 1 mg/L of 4-methyl-2oxopentanoic acid and 5% ethanol, strain BE33A produced 71 mg/L FAEE, with BCFAEE
comprising 66.9% of the total FAEE (Figure 4-3).
Finally, I attempted to generate branched-chain esters with branches at both termini
(branched-chain fatty acid isopropyl esters), through the in vivo transesterification of isopropanol
rather than ethanol. Strain BE33A was supplemented with 5% isopropanol at the point of
induction. Fatty acid esters from BE33A, observed by GC-MS, contained branches at both the
fatty acyl terminus and the ester terminus, reaching 68 mg/L and 61.4% of the total fatty acid
isopropyl esters produced (Figure 4-3). There is no data describing the freezing point of these
branched-chain fatty acid isopropyl esters (BCFAIEs), but theoretically, the freezing point of the
double-branched fatty acyl esters will be lower than that of the esters with a single branched
terminus, increasing the value of the resultant fuel.

4.3.3 α, ω-diol production by switching the fabH and engineering the
precursor formation module
After exploring the different possibilities for product generation module (Module C) to
produce branched-chain alcohols, alkanes and esters, I sought to engineer the acyl-CoA activation
(Module A) and malonyl-ACP consumption module (Module B) to incorporate other ω-functional
groups into fatty acid chain (Figure 3-1). I first chose ω-hydroxy group, because ω-hydroxy fatty
acids and α,ω-diols are valuable precursors to polyesters [152], and the enzyme Pct from M.
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elsdenii has been identified to produce 2-hydroxyacetyl-CoA from 2-hydroxyacetic acid (glycolic
acid).

Figure 4- 4 Biosynthetic pathways to generate ω-hydroxy products
The Acyl-ACP Generation Module (Module B) incorporates ω-hydroxy-acyl-CoA into the fatty
acid biosynthetic pathway. The Product Formation Module (Module C) converts ω-hydroxy-acylACP to ω-hydroxy acid and diols.
I first sought to engineer the Module B by replacing E. coli native fabH with a ω-hydroxy
acyl-CoA-specific fabH using similar strategy described in Chapter 2. Because no FabH has ever
been reported to uptake ω-hydroxy acyl-CoA, I selected the FabH from Alicyclobacillus
acidocaldarius, which was reported to uptake 3-hydroxybutyryl-CoA as a substrate. Strain BC14
carrying

AafabH

was constructed from parental strain CL111(△Kan) through P1 transduction in

the same way as strain BC13. Then plasmids pE8c-pct and pB5k-maqu2220/pB5k-tesA were
transformed into strain BC14 to create the producing strains BC14A and BO14D, respectively.
83

However, when glycolic acid was supplemented in the cell culture, no ω-hydroxy products were
detected in either strains. This result indicated that either

AaFabH

or FASII elongation enzymes

could not uptake ω-hydroxy substrates.

4.4 Discussion
In this chapter, I applied the modular BCFA synthetic pathway to generate biofuels with
desirable cold-flow properties for specific fuels. Strain BA33A can produce branched-chain alkane
with a percentage of 74%, which can be readily used as jet fuel. Similarly, strain BE33A, which
can produce BCFAEE and BCFAIE in high percentages, will also benefit the biodiesel industry.
The next step was to expand the profile of the products from this NNFA biosynthetic pathway
to include bifunctional chemicals. Here I started by incorporating the ω-hydroxy group, but was
unsuccessful, probably due to the unsuitable FabH. On the other hand, to generate ω-hydroxy fatty
acid, the ω-hydroxy group can also be introduced by P450 enzymes after FASII elongation steps
[152]. I tried this pathway to produce α, ω-diols, but it suffered from low titers and the significant
co-production of fatty alcohols (data not shown). This fact also demonstrated the superiority of
this NNFA synthetic pathway to produce ω-functionalized fatty acid derivatives in a high
percentage and called for an effective method to screen and select for suitable FabHs.

4.5 Conclusion
In this chapter, I engineered the BCFA-producing strains to generate branched-chain alkanes
and esters in high percentages, which can be readily used as biofuels with desirable cold-flow
properties. I also explored the possibility of producing ω-hydroxy fatty acids and α,ω-diols by
engineering Module A and Module B in the NNFA synthetic pathway.
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Chapter 5: Establish a cell-free platform for
producing fatty acid and derivatives
5.1 Introduction
The success of BCFA production in engineered E. coli demonstrated the versatility of E. coli FASII
elongation enzymes in accepting substrates with branched terminal groups, paving the way for the
bioproduction of bifunctional fatty-acid-based chemicals, such as ω-hydroxy acids, ω-ethenyl
acids, ω-ethynyl acids, and ω-azido acids. These chemicals have appealing applications: ωhydroxy acids are monomer building blocks for polymers, and acids with ethenyl, ethynyl, or azido
groups have the potential for protein tagging and labelling in protein chemistry. In addition, the
engineered BCFA synthetic pathway can provide a suitable platform to test the capacity of the
FASII enzymes to uptake the ω-functionalized substrates, while the modular pathway engineering
strategy can simplify the test by decoupling it from the generation of acyl-CoA precursors.
However, even with the supplementation of those specific α-keto acids or acyl-CoA precursors,
there would still be several obstacles to running the test in vivo, including the intracellular transport
barriers of the precursors and the toxicity of those bi-functional molecules to the cells. Meanwhile,
the in vitro system offers a complementary approach, which can also overcome other shortages for
in vivo biomanufacturing practices, most notably, these are the cell’s inherent limitations (mainly
the cost of carbon and energy for cell growth, maintenance, and byproduct formation [64]) and the
unwieldy complexity of cells [64-66].
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Although the in vitro reconstitution of the fatty acid synthase in E. coli has been achieved
using purified enzyme systems [88], I chose crude lysates to build this biosynthetic pathway for
several reasons: 1) The fatty acid productivity could be easily affected by the molar ratio of the
FASII enzymes, and the fatty acid overproducing cell lines have molar protein ratios that are close
to optimal; 2) The native metabolic enzymes and cofactor regeneration in the crude lysates will
result in a higher titer than that of the purified systems, which will make identification of products
much easier; 3) The crude lysates inherently provide the context of native-like metabolic networks
[153-156].
Quick and efficient biosynthesis of several chemicals has been achieved with high
productivities by cell-free metabolic engineering (CFME) using crude lysates, such as mevalonate
[155], n-butanol [153], and 2,3-butanediol [157]. In all these cases, the enzymes involved in the
metabolic pathways have been overexpressed. However, considering the robustness and integrity
of FASII enzymes, I used cell endogenous FASII enzymes without any engineering or
overexpression in this work (except heterologous overexpressed FabH). I used several strategies
to construct and optimize the CFME reaction and achieved both straight-chain and branched-chain
fatty alcohol production in vitro.

5.2 Materials and Methods
5.2.1 Strains, plasmids and media
Strains used in this study were listed in Table 5-1. Genes encoding E. coli accABCD was
amplified from the genome and assembled into the pE8c backbone using Golden-Gate DNA
assembly method [65].
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2×YTPG media (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl, 7 g/L KH2PO4, 3 g/L
K2HPO4, 18 g/L glucose) without any antibiotics was used to cultivate cells for lysate preparation.
Table 5- 1 Strains used in Chapter 5
Strains
Relevant genotype
JBEI-9018
MG1655 ΔfadE, araD: acpS (C. glutamicum), pB5k-maqu2220
DH1acc
DH1(ΔfadE) pE8c-accABCD
BC13A
CL111 (plsX’fabH; aadA)::TetA pSa-PecfabH-SafabH, pB5c-tesAbkd
BO33D
CL111 (plsX’fabH; aadA)::TetA, △Kan, fadE::bkd, pSa-PecfabHSafabH, pB5k-maqu2220-lplA

Reference
[121]
This study
Chapter 2
Chapter 3

5.2.2 Cell extract preparation
Cell lysates were prepared using a previously published protocol [158]. In detail, E. coli cells
were pre-cultivated in LB medium with proper antibiotics. Overnight cultures were inoculated 2%
v/v into 2×YTPG minimal medium (described in section 5.2.1) at 37 °C with vigorous shaking at
250 rpm. When OD600 reached 0.8, cells were induced with proper inducers (1mM IPTG, 0.4%
arabinose and/or 200 nM aTc, or as otherwise specified) and grown for 4h at 30 °C. The cells were
harvested by centrifuging at 8000 g at 4 °C for 15 min and were washed twice with ice-cold S30
buffer (10 mM Tris-acetate (pH8.2), 14mM Mg(Ac)2, and 60 mM potassium glutamate). Then the
pelleted wet cells were weighed and suspended in 0.8 mL of S30 buffer per1g wet cell mass.
Suspended cells were lysed using a Qsonica Sonicator Q700 (Qsonica, Newtown, CT) with a 1.6
mm diameter probe at frequency of 20 kHz and 50% of amplitude. The various input energies
(Joules) were used, and the optimal input energies for different strains were identified by following
cell-free protein synthesis (CFPS) reactions. The lysates were then centrifuged twice at 21,100 g
at 4 °C for 15 min. All the prepared cell extracts were flash frozen in liquid nitrogen and stored at
-80 °C until use.
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5.2.3 Protein quantification in cell lysates and CFPS reactions
The total protein concentration of the extracts was measured by Bradford protein assay with
a bovine serum albumin standard. The extracts were subsequently run on a 12% SDS-PAGE gel
with Coomassie-blue staining analysis.
The CFPS reactions were carried out following a published protocol [158]. In detail, a 25 μl
CFPS reaction was prepared by mixing the following components in a 1.5 mL microtube: 1.2 mM
ATP; 0.85 mM each of GTP, UTP, and CTP; 34.0 mg/mL L-5-formyl-5, 6, 7, 8-tetrahydrofolic
acid (folinic acid); 170.0 mg/mL of E. coli tRNA mixture; 130 mM potassium glutamate; 10 mM
ammonium glutamate; 12 mM magnesium glutamate; 2 mM each of 20 amino acids; 0.33 mM
nicotinamide adenine dinucleotide (NAD); 0.27 mM coenzyme-A (CoA); 1.5 mM spermidine; 1
mM putrescine; 33 mM phosphoenolpyruvate (PEP); 13.3 mg/mL plasmid pJL1-sfGFP; 100
mg/mL T7 RNA polymerase, and 10 mg/mL of cell extract. The CFPS reactions were carried out
at 37 °C for 24 h. For each sample, 2 μL of reaction mix was diluted with 48 μL of purified water,
and the fluorescence of active sfGFP was measured by an Infinite F200PRO (TECAN) plate reader
at excitation and emission wavelengths of 485 and 528 nm, respectively.

5.2.4 CFME reactions and products quantification
Reactions were carried out at 37 °C in 25 μl volumes for 4 h (or as otherwise specified). Each
reaction consisted of mixing the cell-extracts along with 8 mM magnesium glutamate, 10 mM
ammonium glutamate, 134 mM potassium glutamate, 10 mM K2HPO4 (pH = 7.2), 100mM BisTris,
and various substrates and cofactors. Reactions were terminated by adding ethyl acetate in a 1:1
ratio. Then products were extracted and analyzed following the methods in section 2.2.4 and 3.2.5.
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5.3 Results
5.3.1 Cell-free metabolic engineering for fatty acid production
To achieve cell-free biosynthesis of fatty acids, I first used strain BC13A for lysis and extract
preparation. Various conditions were set up to produce straight-chain or branched-chain fatty acid
as shown in Table 5-2 (A-D). The reaction mixtures were incubated at 37 °C for 4 h, then the
amount of fatty acids in each sample was measured using previous analytical methods. As this was
the first trial to test whether in vitro production of fatty acid from CFME reaction was even feasible,
so I just used a well-established reaction protocol from Jewett Lab in Northwestern University.
Further investigation and/or optimization of the reaction buffer setting/running time might be
performed after the verification of the feasibility.
However, more than 30 mg/L C18:0 fatty acid (stearic acid) was observed in all the conditions
(Figure 5-1), which the exceeded the theoretical yield (9 mg/L in the form of C18:0 fatty acid)
calculated from the supplied NADPH. I sought to trace the source of the excess FFA by setting up
different control reactions (Table 5-2 E-H). A high amount of FFA was detected in all the sources
(Figure 5-1), including water, all the reagents, and the cell extract, which indicated that the detected
FFA came from universal contamination rather than the reactions.
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Table 5- 2 Reactions for fatty acid production from CFME
A
B
C
D
E
15× SS
1×
1×
1×
1×
1×
glucose (mM)
200
---200
acetyl-CoA
-25
-25
-α-keto acid (g/L)
--1
1
1
K2HPO4 (mM)
10
-10
-10
Bis Tris Buffer (mM)
100
-100
-100
NAD+ (mM)
0.5
-0.5
-0.5
NADP+ (mM)
0.5
-0.5
-0.5
NADPH (mM)
-1
-1
-ATP (mM)
1
1
1
1
1
CoA (mM)
0.5
-0.5
-0.5
BC13A lysate (mg/mL)
10
10
10
10
--

F
1×
-25
1
----1
1
---

G
-------------

H
-----------10

Figure 5- 1 Fatty acid production from CFME reactions

Because the amounts of detected FFA were comparable, indicating they were introduced from
common steps, I assumed that the FFA contamination resulted from three external major sources:
the surface of the tubes, the water used, and the incubation process. The effect of each factor was
quantified by setting up various reactions (Supplementary Table 5-1). The results showed that the
contamination induced during incubation was negligible (data not shown), but a large amount of
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C16:0 and C18:0 fatty acids was introduced from the tube and water (Supplementary section). For
a 25 μL reaction in a 1.5 mL tube, the C18:0 fatty acid contamination from the environment was
roughly 20 mg/L.

5.3.2 Cell-free metabolic engineering for fatty alcohol production
Considering the difficulty of eliminating FFA contamination from the environment, I switched
to the fatty alcohol pathway for this research. After confirming that no fatty alcohol would be
introduced from the environment, I lysed two strains to generate cell extracts for straight-chain
and branched-chain alcohol productions. Strain JBEI-9018 was reported to produce the highest
amount of straight-chain alcohols to date [121], while BO33D strain is currently the best
performing strain for branched-chain alcohol production.
I first tested the feasibility of the cell extracts to produce fatty alcohols in vitro by setting up
a series of reactions (Table 5-3). Similarly, I used the same well-established protocol to run the
reactions. Reaction O was set to detect the trace amount of alcohol in all the reagents and cofactors,
while reactions A- and B- were used to evaluate the alcohol amounts in the cell extracts. All the
reactions started with acetyl-CoA and malonyl-CoA as the substrate to uncouple the FASII
synthesis from other endogenous reactions (such as glycolysis), and 4-methyl-2-oxopentanoic acid
was supplemented as the precursor for branched-chain fatty alcohol production.
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Table 5- 3 Reactions to produce fatty alcohols from CFME
O
AA+
JBEI-9018
-10 mg/mL
10 mg/mL
lysate
BO33D lysate
---Acetyl-CoA
25 mM
-25 mM
Malonyl-CoA
0.5 mM
-0.5 mM
Keto acid
1 g/L
--NADPH
1 mM
-1 mM
ATP
1 mM
-1 mM
15× SS
1×
1×

B--

B+
--

10 mg/mL
------

10 mg/mL
-0.5 mM
1 g/L
1 mM
1 mM
1×

The comparison between A- and A+ indicated that 2 mg/L of C18:0 alcohol (stearyl alcohol)
was produced in vitro. Similarly, with supplemented α-keto acid, 1 mg/L of C17:0 iso alcohol (15methyl-1-hexadecanol) was generated from reaction B+ (Figure 5-2). Both results demonstrated
that all the enzymes involved in alcohol producing pathway, including FASII elongation enzymes,
BKD, and Maqu2220 were active in the cell lysates. However, more than 20 mg/L of C16:0 alcohol
was detected in both cell lysates, even without any substrates or cofactors, which made the
identification of the in vitro produced portion impossible.

Figure 5- 2 Fatty alcohol production from CFME reactions
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5.3.3 Improve the cell-free platform for fatty alcohol production
I reasoned that a large amount of C16:0 alcohol might be generated during the post-induction
incubation, that is, once the Maqu2220 was overexpressed, it would immediately convert acylACPs to alcohols during the incubation before lysis. Therefore, I designed two ways to
differentiate this portion with in vitro produced portion: one way is to attenuate the in vivo
produced portion, and the other is to increase the in vitro produced portion.
I first decreased the cell extract concentration in hope to directly decrease the in vivo produced
portion. However, when the cell extract concentration was decreased to 1 mg/mL, although no
C16:0 alcohol was detected in all the reactions, the concentrations of C18:0 and C17:0 iso products,
which were identified as synthesized in vitro, were also below the detection limit. This result
indicated that the FASII enzymes and/or the Maqu2220 enzyme need to be accumulated to a
threshold to run the cell-free reactions and to produce detectable amount of the alcohols. While
under this threshold, it is almost impossible to omit the in vivo produced portion using the cell
extract from a single strain.
As direct decreasing the in vivo produced portion was unsuccessful, I sought to increase the
in vitro produced portion by studying the necessity of the substrates and cofactors, i.e. acetyl-CoA,
malonyl-CoA, and NADPH. Some of the cofactors might either already exist or be regenerated in
the cell lysate, but the low titer in section 5.3.2 demonstrated that at least one of the substrates or
cofactors would be the limiting step. Reactions A1-A5 were carried out using the cell extract from
JBEI-9018 (Table 5-4), and the results clearly showed that external malonyl-CoA is required for
in vitro fatty alcohol production (Figure 5-3A). I also evaluated the impact of the malonyl-CoA
amount on in vitro branched-chain fatty alcohol production by setting up reactions B1 to B3 with
various malonyl-CoA concentrations (Table 5-4). When the malonyl-CoA concentration was
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increased by 6-fold, the C17:0 iso titer increased by 8-fold (Figure 5-3B). Again, no branchedchain product was observed in reaction B3 lacking malonyl-CoA.
Table 5- 4 Cofactor necessity test for fatty alcohol production from CFME
A1
A2
A3
A4
A5
B1
B2
JBEI- JBEI- JBEI- JBEI- JBEICell lysate (10 mg/mL)
BO33D BO33D
9018 9018 9018 9018 9018
Acetyl-CoA (mM)
25
-25
-25
--Malonyl-CoA (mM)
0.5
--0.5
0.5
3
0.5
Keto acid (g/L)
-----1
1
NADPH (mM)
-1
1
1
1
1
1
ATP (mM)
1
1
1
1
1
1
1
15× SS
1×
1×
1×
1×
1×
1×
1×

B3
BO33D
--1
1
1
1×

Figure 5- 3 The role of different cofactors in fatty alcohol production from CFME reactions

5.3.4 Straight-chain fatty alcohol production from lysate mix
Although I found that the malonyl-CoA is the limiting resource for in vitro production, I could
not supplement it to a very high concentration, due to its solubility and high price. Thus, I next
sought to overexpress the accABCD operon to endogenously produce malonyl-CoA from acetylCoA. However, the overexpression of accABCD was reported to increases the rate of fatty acid
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biosynthesis. Considering that a large proportion of C16:0 alcohol was already generated in vivo
before the cell lysis process in a maqu2220 overexpressed strain, I decided to separate the
overexpression of accABCD from the maqu2220 overexpressed strain. Here I overexpressed these
two operons in two strains and mix their cell lysates to reduce the in vivo production.
The accABCD operon was overexpressed in strain DH1(△fadE) to create strain DH1acc. The
lysate of DH1acc was mixed with that of JBEI-9018 at two different ratios for a rough optimization
(Table 5-5 A0 to A2 vs. B0 to B2). The total amount of the cell lysates was kept at 10 mg/mL to
guarantee the performance of FASII enzymes in vitro. I used glucose rather than acetyl-CoA as
the substrate, because glycolysis has been reported to be active in cell-extract. Considering about
the conversion of glucose to acetyl-CoA, and their solubilities and prices, the use of glucose would
undoubtedly increase the acetyl-CoA pool in the reaction, which might increase the product titer.
Additionally, malonyl-CoA was supplemented in reaction A2 and B2 to evaluate the accABCD
efficiency.
Table 5- 5 Mix and match approach for straight-chain alcohol production from CFME
A0
A1
A2
B0
B1
B2
JBEI-9018 (mg/mL)
9
9
9
5
5
5
DH1acc (mg/mL)
1
1
1
5
5
5
Glucose (mM)
-200
200
-200
200
Malonyl-CoA (mM)
--0.5
--0.5
K2HPO4 (mM)
10
10
10
10
10
10
Bis Tris Buffer (mM)
100
100
100
100
100
100
NAD+ (mM)
0.5
0.5
0.5
0.5
0.5
0.5
+
NADP (mM)
0.5
0.5
0.5
0.5
0.5
0.5
CoA (mM)
0.5
0.5
0.5
0.5
0.5
0.5
15× SS
1×
1×
1×
1×
1×
1×

Surprisingly, no fatty alcohol was detected in the cell mix (reaction A0 and B0), which
demonstrated the effectiveness of the mixture in reducing the final concentration of in vivo
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produced alcohols. Also, no fatty alcohol was generated in vitro in reactions A1 and A2, indicating
that the Maqu2220 amount was not sufficient when the JBEI-9018 cell extract concentration was
only 1 mg/mL. Reaction B1 produced 5 mg/L total fatty alcohol, a 2.5-fold enhancement compared
to the titer of reaction A+ in section 5.3.2 (Figure 5-5), as expected that glucose will yield a higher
titer than acetyl-CoA when used as the sole substrate. Moreover, reaction B2 produced 7 mg/L
total fatty alcohol, indicating that AccABCD amount in this reaction needed further optimization.

Figure 5- 4 Fatty alcohol production from lysate mix

5.4 Discussion
In this chapter, I tried to develop a new cell-free framework for in vitro fatty acid production.
Unlike previous published CFME, this framework relied heavily on E. coli native fatty acid
biosynthetic pathway. Once the enzyme catalyzing the final step, Maqu2220, was overexpressed
in the strain, fatty alcohols were accumulated even before the cells were lysed. Therefore, how to
differentiate the in vitro synthesized products from in vivo products generated after induction
remained a big challenge. Here I decreased the in vivo proportion of the fatty alcohol in the reaction
by diluting the JBEI-9018 cell extract with the cell extract from a non-alcohol-producing strain.
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The result is a proof-of-concept for both straight-chain and branched-chain fatty alcohol
production via CFME.
Although I have achieved the in vitro alcohol production, a lot of parameters and conditions
could be further investigated and optimized. First, there are two different reaction buffers used in
Jewett Lab, gluconate-based buffer and acetate-based buffer. Here I chose gluconate-based buffer
due to its excellent performance in 1-butanol production, but I did not have a solid evidence that
the same buffer will improve long-chain alcohol production. Second, although I have identified
that malonyl-CoA is the rate-limiting factor, the limits for the maximum amounts of all the
substrates and cofactors are still unknown. Then, by careful examination, it is highly possible that
the titer would increase by several folds using the maximum limits of all the reagents.
More importantly, after characterizing the maximum limit of all the reagents (which indicate
the reaction capacity), the amounts of enzymes could also be tuned to improve the reaction capacity.
For example, the overexpression of FASII enzymes individually in the cells for lysate preparations,
followed by mixing and matching lysates in cell-free cocktails might provide another strategy to
increase the reaction capacity and dilute the in vivo portion of the fatty alcohol while enhancing
the in vitro production. However, because FabH plays an essential role in incorporating ωfunctionalized acyl-CoA, E. coli native FabH needs to be cleared in all the cell extracts. The △fabH
strain in the K.O. collection is a promising parental strain, but the effects of its endogenous
regulations on protein synthesis remain unclear. For instance, when pA5a-maqu2220 plasmid was
transformed into the △fabH strain, the cells grew very slowly (data not shown), and no Maqu2220
was detected by SDS-PAGE (Supplementary Figure 5-1).
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Therefore, to further improve the titer for either scale-up production or product identification,
a large number of reactions are required to be carried out to optimize the reaction buffer, the
reaction condition, the optimal amount of all the reagents and the ratio of the cell extracts.
Meanwhile, cell-free protein synthesis (CFPS) offers a complementary solution to fast enrich
the enzymes separately before adding into the reactions. The CFPS-ME framework will also
enable rapid prototyping of ω-functionalized fatty alcohol production from the combination of
FASII with specific FabH. With the progress of bioinformatics, this platform can be further applied
for fast screening of optimal enzyme combinations for the production of bifunctional fatty acid
derivatives.

5.5 Conclusion
In this chapter, I established a new cell-free framework for in vitro fatty alcohol production
and characterized the necessity of several cofactors. The production of both straight-chain and
branched-chain fatty alcohol from this cell-free framework has been achieved. In addition, I
overcame a major obstacle arising from the fact that fatty acid synthesis is an endogenous pathway.
A large proportion of fatty alcohol was produced in vivo during the post-induction incubation time
but was diluted in the final reaction solution through the mix-and-match approach. This result is a
proof-of-concept for fatty alcohol production via CFME and provides guidance for future CFPSME frameworks to produce bifunctional fatty acid derivatives, while intensive optimizations are
still needed before the goal could be achieved.
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Supplementary Materials
Quantification of FFA contamination from three major sources.
Steps:
1. Prepare the reactions as listed below
Supplementary Table 5-1 Recipes for quantification of FFA contamination
1
2
3
4
5
6
7
Water (μL)
25
50
300
50
100
150
300
Tube (mL)
0.5
0.5
0.5
1.5
1.5
1.5
1.5
Incubation
Yes
No
No
Yes
No
Yes
No
Ethyl Acetate (μL)
25
25
150
50
50
150
150

8
500
1.5
Yes
500

9
1000
1.5
No
500

1) For samples that need incubation (1, 4, 6, 8), add the indicated amount of water into 1.5 mL
tubes and incubate at 37 °C for 4 h;
2) Add the same amount of water into those tubes. For sample 1, transfer into 0.5 mL tubes for
extraction;
3) Prepare the samples 2, 3, 5, 7, 9;
2. Extract each sample with the indicated amount of ethyl acetate twice and derivatize and inject
as usual;
3. Normalize the final concentration as the concentration in water;
4. Calculate the FA concentrations in all the samples
1) Models for C16:0 fatty acid

99

2) Models for C18:0 fatty acid

Supplementary Figure 5-1 SDS-PAGE results for protein expression in △fabH strain
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Chapter 6: Conclusion and future directions
6.1 Conclusions
In this work, I have established a modular pathway for producing NNFA and derivatives
production. To start, I achieved branched-chain fatty acid production. In Chapter 2, I directed the
carbon flux to the synthesis of BCFAs by replacing the acetyl-CoA-specific E. coli FabH, the only
β-ketoacyl-(acyl-carrier-protein) synthase that catalyzes the initial fatty acid condensation reaction,
with a branched-chain-acyl-CoA-specific FabH, enhancing BCFA titer by 81-fold over a strain
containing both acetyl-CoA- and branched-chain-acyl-CoA-specific FabHs. I further discovered
that the overexpression of BKD, a member of the 2-oxoacid dehydrogenase family needed to
synthesize branched-chain-acyl-CoA precursors, is toxic to E. coli due to depletion of the protein
lipoylation capacity. Engineering a complementary protein lipoylation pathway alleviated the
toxicity and improved BCFA production to 276 mg/L and 85% of total free fatty acids, the highest
BCFA titer and percentage to-date. Furthermore, I achieved fine-tuning of BCFA branch positions
by engineering the upstream pathway to control the supply of branched-chain acyl-CoAs,
eventually producing 181 mg/L BCFA at 72% of total FFA from glucose.
In Chapter 3, I partitioned the complete pathway into three modules: a precursor formation
module (the α-Keto Acid Synthesis Module), an acyl-CoA activation and malonyl-ACP
consumption module (the Acyl-ACP Generation Module), and a final product synthesis module
(the Alcohol Formation Module). I engineered and tuned each module separately and combined
the optimal modules to produce a high percentage of branched fatty alcohols from glucose. In
Chapter 4, I further utilized this modular pathway engineering strategy to produce branched-chain
alkanes and esters. I also tested the feasibility of ω-hydroxy fatty acid production by engineering
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the precursor formation module. In Chapter 5, I moved the modular NNFA synthetic pathway into
a new cell-free framework to give a proof-of-concept for in vitro production of fatty acid
derivatives and provided guidance for future CFPS-ME framework to produce bifunctional fatty
acid derivatives.
Overall, this work establishes a platform for the microbial synthesis of branched biofuels and
chemical in high percentages, paving the way for bioproduction of structurally-defined molecules
with desired properties.

6.2 Future directions
In this work, although I have established a modular pathway platform to produce non-natural
fatty acids, I have achieved the production of only branched-chain fatty acid and derivatives.
Diversifying the ω-terminal structure requires comprehensive studies on the precursor formation
module and the acyl-CoA activation and malonyl-ACP consumption module. The enzyme
selection, screening, and pathway prototyping can be facilitated by bioinformatics and the CFPSME framework. Thus, one future direction would be the optimization of all the factors in current
CFME framework, and the establishment of an improved CFPS-ME platform to perform the
prototyping work.
Meanwhile, although the titer of straight-chain fatty acid and alcohol production can reach
more than 3 g/L, the results from this dissertation showed that their branched-chain counterparts
can be produced only at the level of 200 mg/L. Since the low titer might result from the metabolic
burden caused by protein synthesis and/or product accumulation, studying the metabolic limits of
the engineered strains will be another future direction. In detail, the burden caused by protein
synthesis, NADP+/NADPH recycling, and BCFA intracellular distribution, are potential research
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targets to study about in the fatty acid synthetic pathway. In addition, the heterogeneity of
producing cells has been demonstrated to affect ensemble production [22, 23], so studies on cellto-cell variations based on this platform are other potential directions, including the strategy to
enrich the high-producing variants and ultimately enhance product titers. These studies will
provide a general strategy to improve cell performance in metabolic engineering.
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